Suppressive myeloid cells are a hallmark of severe COVID-19

- 3 Jonas Schulte-Schrepping^{1*}, Nico Reusch^{1*}, Daniela Paclik^{2*}, Kevin Baßler^{1*}, Stephan
- 4 Schlickeiser^{3*}, Bowen Zhang^{4*}, Benjamin Krämer^{5*}, Tobias Krammer^{6*}, Sophia Brumhard^{7*},
- 5 Lorenzo Bonaguro^{1*}, Elena De Domenico^{8*}, Daniel Wendisch^{7*}, Martin Grasshoff⁴, Theodore S.
- 6 Kapellos¹, Michael Beckstette⁴, Tal Pecht¹, Adem Saglam⁸, Oliver Dietrich⁶, Henrik E. Mei⁹, Axel
- 7 R. Schulz⁹, Claudia Conrad⁷, Désirée Kunkel¹⁰, Ehsan Vafadarnejad⁶, Cheng-Jian Xu^{4,11}, Arik
- 8 Horne¹, Miriam Herbert¹, Anna Drews⁸, Charlotte Thibeault⁷, Moritz Pfeiffer⁷, Stefan
- 9 Hippenstiel^{7,12}, Andreas Hocke^{7,12}, Holger Müller-Redetzky⁷, Katrin-Moira Heim⁷, Felix Machleidt⁷,
- 10 Alexander Uhrig⁷, Laure Bousquillon de Jarcy⁷, Linda Jürgens⁷, Miriam Stegemann⁷, Christoph
- 11 R. Glösenkamp⁷, Hans-Dieter Volk^{2,3,13}, Christine Goffinet^{14,15}, Jan Raabe⁵, Kim Melanie Kaiser⁵,
- 12 Michael To Vinh⁵, Gereon Rieke⁵, Christian Meisel¹⁴, Thomas Ulas⁸, Matthias Becker⁸, Robert
- 13 Geffers¹⁶, Martin Witzenrath^{7,12}, Christian Drosten^{14,19}, Norbert Suttorp^{7,12}, Christof von Kalle¹⁷,
- 14 Florian Kurth^{7,18}, Kristian Händler⁸, Joachim L. Schultze^{1,8,#,\$}, Anna C Aschenbrenner^{20,#}, Yang
- 15 Li^{4,#}, Jacob Nattermann^{5,19,#}, Birgit Sawitzki^{2,#}, Antoine-Emmanuel Saliba^{6,#}, Leif Erik Sander^{7,12#},
- 16 Deutsche COVID-19 OMICS Initiative (DeCOI)
- 17 * shared first authors, # shared last authors, \$ corresponding author

Affiliations

18

19

1

2

- 20 1 Life & Medical Sciences (LIMES) Institute, University of Bonn, Germany
- 21 2 Institute of Medical Immunology, Charité, Universitätsmedizin Berlin, Berlin, Germany
- Institute of Medical Immunology, Charité, Universitätsmedizin Berlin, Berlin, Germany & BIH Center for Regenerative Therapies, Charité and Berlin Institute of Health, Charité, Universitätsmedizin Berlin, Berlin, Germany.
- 25 4 Centre for Individualised Infection Medicine (CiiM) & TWINCORE, joint ventures between the 26 Helmholtz-Centre for Infection Research (HZI) and the Hannover Medical School (MHH), Hannover, 27 Germany
- 28 5 Department of Internal Medicine I, University Hospital Bonn, Bonn Germany
- Helmholtz Institute for RNA-based Infection Research (HIRI), Helmholtz-Center for Infection Research (HZI), Würzburg, Germany
- Department of Infectious Diseases and Respiratory Medicine, Charité Universitätsmedizin Berlin,
 Berlin, Germany
- 33 8 PRECISE Platform for Single Cell Genomics and Epigenomics, German Center for Neurodegenerative Diseases, Bonn, Germany and University of Bonn, Bonn Germany
- 35 9 Mass Cytometry Lab, DRFZ Berlin, a Leibniz Institute, Berlin, Germany
- 36 10 Flow & Mass Cytometry Core Facility, Charité Universitätsmedizin Berlin and Berlin Institute of Health (BIH), Berlin, Germany
- 38 11 Department of Internal Medicine and Radboud Center for Infectious Diseases, Radboud University
 39 Medical Center, Nijmegen, the Netherlands
- 40 12 German Center for Lung Research (DZL)

- Institute of Medical Immunology, Charité, Universitätsmedizin Berlin, Berlin, Germany, Labor Berlin Charité Vivantes, Department of Immunology, Berlin, Germany
- 43 14 Institute of Virology, Charité Universitätsmedizin Berlin, Berlin, Germany
- 44 15 Berlin Institute of Health, 10178 Berlin, Germany
- 45 16 Genome Analytics, Helmholtz-Center for Infection Research (HZI), Braunschweig, Germany
- 46 17 Clinical Study Center (CSC), Berlin Institute of Health (BIH), and Charite Universitätsmedizin Berlin, 47 Germany
- Department of Tropical Medicine, Bernhard Nocht Institute for Tropical Medicine & I. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
- 50 19 German Center for Infection Research (DZIF)
- 51 20 Life & Medical Sciences (LIMES) Institute, University of Bonn, Germany and Radboud UMC, 52 Nijmegen, The Netherlands

Key Words:

61

- 59 COVID-19, SARS-CoV-2, monocytes, immunosuppressive neutrophils, neutrophils,
- 60 immunosuppressive neutrophils, scRNA-seq, mass cytometry, CyTOF

Abstract

62

63

64

65

66 67

68

69

70 71

72

73 74

75

76

77 78

79

80

81 82 83

'Severe Acute Respiratory Syndrome - Coronavirus-2' (SARS-CoV-2) infection causes Coronavirus Disease 2019 (COVID-19), a mild to moderate respiratory tract infection in the majority of patients. A subset of patients, however, progresses to severe disease and respiratory failure with acute respiratory distress syndrome (ARDS). Severe COVID-19 has been associated with increased neutrophil counts and dysregulated immune responses. The mechanisms of protective immunity in mild forms and the pathogenesis of dysregulated inflammation in severe courses of COVID-19 remain largely unclear. Here, we combined two single-cell RNA-sequencing technologies and single-cell proteomics in whole blood and peripheral blood mononuclear cells (PBMC) to determine changes in immune cell composition and activation in two independent dualcenter patient cohorts (n=46+n=54 COVID-19 samples), each with mild and severe cases of COVID-19. We observed a specific increase of HLA-DRhiCD11chi inflammatory monocytes that displayed a strong interferon (IFN)-stimulated gene signature in patients with mild COVID-19. which was absent in severe disease. Instead, we found evidence of emergency myelopoiesis, marked by the occurrence of immunosuppressive pre-neutrophils and immature neutrophils and populations of dysfunctional and suppressive mature neutrophils, as well as suppressive HLA-DR^{lo} monocytes in severe COVID-19. Our study provides detailed insights into systemic immune response to SARS-CoV-2 infection and it reveals profound alterations in the peripheral myeloid cell compartment associated with severe courses of COVID-19.

Introduction

84

85 86

87 88

89 90

91

92 93

94

95

96 97

98

99

100

101102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in December of 2019 (Wu et al., 2020) and the subsequent pandemic spread of Coronavirus Disease 2019 (COVID-19) has caused immense morbidity and mortality around the world (Fauver et al., 2020: Zhou et al., 2020b). Clinical presentations of COVID-19 are variable, and while the majority of patients experiences mild to moderate symptoms, a subset of 10-20% of patients develops pneumonia and severe disease (Brignola et al., 1988; Guan et al., 2020a; Huang et al., 2020; Wang et al., 2020b; Zhou et al., 2020a). Clinical deterioration and development of respiratory failure and acute respiratory distress syndrome (ARDS), typically develops in the second week of disease. Besides protracted viral replication, this kinetic suggests a role for secondary immune responses in the development of severe COVID-19 (Ziying Ong et al., 2020). However, the exact mechanisms that govern the pathophysiology of the different disease courses of COVID-19 remain ill-defined. Patients with comorbidities, including hypertension, diabetes, COPD, cardiovascular disease, and cerebrovascular disease are at highest risk to develop severe COVID-19 (Guan et al., 2020b; Wang et al., 2020a). Given that these conditions are associated with chronic inflammation, disease severity of COVID-19 might be closely linked to the underlying specific and nonspecific immune response to the virus.

SARS-CoV-2 was identified as the causative agent of COVID-19 (Wu et al., 2020) and similar to SARS coronavirus, it uses ACE2 as the primary cellular entry receptor (Hoffmann et al., 2020; Li et al., 2003). SARS-CoV-2 has a tropism for the upper airways and the lung (Wölfel et al., 2020). despite rather low numbers of cells that co-express ACE2 and the essential cofactor for ACE2 binding, TMPRSS2 (Allan et al., 2020; Qi et al., 2020; Sungnak et al., 2020; Ziegler et al., 2020), but the expression of ACE2 and TMPRSS2 in airway epithelial cells are increased by type-I IFN stimulation (Ziegler et al., 2020). Single cell studies of bronchoalveolar lavage samples have suggested a complex dysregulation of the pulmonary immune response in severe COVID-19 (Liao et al., 2020). Overall, systemic inflammation is linked to an unfavorable clinical course of disease and the development of severe COVID-19 (Giamarellos-Bourboulis et al., 2020; Ziying Ong et al., 2020). SARS-CoV2 infection induces specific T cell and B cell responses, which is reflected by elevation of SARS-CoV-2 peptide-specific T cells (Braun et al., 2020; Grifoni et al., 2020) and the production of SARS-CoV-2 specific antibody responses (Long et al., 2020; Ni et al., 2020). Patients with severe COVID-19 have high systemic levels of inflammatory cytokines, specifically IL-1β and IL-6 (Chen et al., 2020; Giamarellos-Bourboulis et al., 2020; Ziying Ong et al., 2020), whereas interferon (IFN) responses appear to be impaired as shown by whole blood transcriptomics (Hadjadj et al., 2020). Clinical observations and several studies indicate an increase of neutrophils and a decrease of non-classical (CD14loCD16hi) monocytes in severe COVID-19 (Hadjadj et al., 2020; Merad and Martin, 2020). Severe immune dysregulation is a common phenomenon in sepsis, characterized by a progression from hyperinflammatory states to immunosuppression (Remy et al., 2020; Ritchie and Singanayagam, 2020) and similar mechanisms have been proposed for severe COVID-19 (Giamarellos-Bourboulis et al., 2020), yet mechanistic insights are still missing. Exacerbated immune responses play a major role in the pathophysiology of SARS, leading to severe lung injury and respiratory failure (Perlman and Dandekar, 2005). Mitigation of immunodysregulation could thus represent a major therapeutic

avenue for the treatment and prevention of severe COVID-19 (Dimopoulos et al., 2020; Jamilloux et al., 2020). An early report investigating transcriptional profiles of peripheral blood mononuclear cells (PBMC) of 7 patients with mixed clinical courses of COVID-19, revealed complex immune deviations with changes in numerous cellular compartments, including monocytes, NK cells, dendritic cells and T cells (Salomé and Mahmood, 2020; Wilk et al., 2020).

127

128

129

130

131

132133

134

135

136

137

138

139

140

141

142

143

144145

146

147

148

149

150

The heterogeneity of clinical phenotypes and the complexity of systemic immune responses to COVID-19 highlight the need for detailed insights into different stages of the disease using highresolution techniques and well-characterized clinical cohorts. Here, we hypothesized that distinct immune responses, particularly within the innate immune cell compartment, underlie the different clinical trajectories of COVID-19 patients (McKechnie and Blish, 2020). The striking alterations in cell counts and activation states of different innate immune cells in COVID-19 patients, and their relation to disease severity are currently not sufficiently understood. Here, we performed singlecell transcriptomics and single-cell proteomics on blood samples from two independent cohorts of COVID-19 patients, which allowed for instant cross-validation of immunological findings. COVID-19 patients with mild disease courses in both cohorts showed increased CD14+HLA-DRhiCD11chi inflammatory monocytes, which were marked by a strong IFN-stimulated gene (ISG+) signature. In contrast, severe COVID-19 was associated with the appearance of immature CD14⁺MPO⁺Ki67⁺HLA-DR^{lo} ISG⁺ suppressive monocytes and dysfunctional low-density neutrophils. latter were identified as ARG1⁺MPO⁺BPI⁺ pre-neutrophils ARG1+CD101+S100A8/A9+ immature neutrophils, indicative of emergency myelopoiesis. In addition, suppressive PD-L1+CD123+ neutrophils were detected at late stages in severe COVID-19. Collectively, our study links highly dysregulated myeloid cell responses to severe disease courses of COVID-19.

Results

151

152153

154

155

156

157

158

159 160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187 188

189

190

191

Dual center cohort study to assess immunological alterations in COVID-19 patients

In order to gain detailed insights into the distinct immunological events in mild *versus* severe COVID-19, we analyzed peripheral blood samples collected from independent cohorts of COVID-19 patients at two university medical centers in Germany. Samples from the Berlin cohort (cohort 1) were analyzed by mass cytometry (CyTOF) and single-cell RNA-sequencing (scRNA-seq) using a droplet-based single cell platform (10x Chromium), while samples from the Bonn cohort (cohort 2) were analyzed by multi-colour flow cytometry (MCFC) and scRNA-seq using a microwell-based system (BD Rhapsody). We profiled a total of 8.1 million cells by their surface protein markers and over 210,000 cells by scRNA-seq in 131 samples derived from a total of 33

COVID-19 patients and 23 controls (Fig. 1A+B, S1A, Table S1).

We delineated COVID-19-induced alterations of the major leukocyte lineages by mass cytometry on whole blood samples from COVID-19 patients collected between day 6 and day 13 after disease symptom onset and compared them to age-matched healthy controls. Two antibody staining panels were designed to capture alterations in mononuclear cells (lymphocytes, monocytes and dendritic cells, panel 1), and in the granulocyte compartment (panel 2), respectively (Table S2). High-resolution SPADE analysis was performed with 400 target nodes and individual nodes were aggregated into cell subsets according to the expression of lineagespecific cell markers, such as CD14 for monocytes and CD15 for neutrophils (Fig. S1B). Visualization of t-distributed stochastic neighbor embedding (viSNE)-automated analysis revealed a clear separation of samples from COVID-19 patients and healthy controls, with marked changes of the monocyte- and the granulocyte compartment (Fig. 1C). Comparison of healthy control samples utilized for mass cytometry (HC CyTOF) to MCFC data from our recently published cohorts of healthy controls (HC flow) (Kverneland et al., 2016), demonstrated high similarities in the proportions of granulocytes, lymphocytes, T cells, total monocytes and CD14^{lo}CD16^{hi} 'non-classical' monocytes in whole blood samples from healthy controls, irrespective of the applied methodology (Fig. 1D). This allowed us to use the absolute numbers of the published cohorts to also report differences in absolute numbers in COVID-19 samples. In line with recent reports (Barnes et al., 2020; Xintian et al., 2020), we observed a marked leukocytosis with increased proportions of granulocytes and neutrophils in patients with severe COVID-19 (Fig. 1D). In contrast, total lymphocyte- and T cell numbers were strongly reduced in all COVID-19 patients. Furthermore, we found a significant reduction of monocytes, particularly non-classical monocytes were virtually absent in COVID-19 (Fig. 1D). These changes, increased neutrophils in severe COVID-19 and loss of non-classical monocytes in both mild and severe disease, were validated in cohort 2 by MCFC (Fig. S1C).

Thus, SARS-CoV-2 infection induces lymphopenia and strong alterations within the myeloid compartment, with a drastic reduction of non-classical monocytes and neutrophilia in severe cases of COVID-19.

Severity-dependent alterations of the myeloid cell compartment in COVID-19

192

193194

195

196

197

198

199

200

201

202203

204

205

206

207

208

209

210

211

212

213

214

215

216

217218

219

220

221

222223

224

225

226

227

228

229

230

231

232

233

234

235

Given the dramatic changes in various immune cell populations in COVID-19 (Fig. 1C+D), we next assessed their composition and activation status during the course of SARS-CoV-2 infection by droplet-based scRNA-seq in 21 samples from 12 COVID-19 patients (4 mild & 8 severe, cohort 1, Table S1) collected between day 7 and day 20 after disease symptom onset. A total of 25,667 single-cell transcriptomes of PBMC were analyzed together with 22,418 PBMC from a publicly available control dataset (4 healthy donors). Two-dimensional data representation using Uniform Manifold Approximation and Projection (UMAP) and high-resolution cell type classification identified all major cell types expected in the mononuclear compartment of blood, with a high granularity in the monocyte compartment as indicated by identification of four monocyte subsets (cluster 2, 5, 12, 14) (Fig. 2A). The top 10 genes identifying each cluster can be found in Fig. S2A. Monocytes in cluster 2, 5, and 14 expressed CD14, whereas cluster 12 comprised the nonclassical monocytes marked by FCGR3A (CD16a). Separate visualization of cells in mild and severe cases, revealed highly disease severity-specific clusters (Fig. 2B). A distinct subset of the CD14⁺ monocytes marked by high expression of interferon (IFN)-stimulated genes (ISG, cluster 5), including ISG15, IFI6, IFITM3, or APOBEC3A (Fig. 2C), was selectively detected in mild COVID-19. The most prominent change in severe COVID-19, however, was the appearance of two cell populations (cluster 9+13, Fig. 2B), that were absent in PBMC of patients with mild COVID-19 and healthy donors. Based on published markers, the cell populations were identified as neutrophils and immature neutrophils (Fig. 2A+B). The immature neutrophils (cluster 13) expressed CD24, MMP8, DEFA3 and DEFA4, whereas the identified neutrophil population (cluster 9) was marked by FCGR3B (CD16b), CXCL8 (IL-8) and CSF3R (G-CSF receptor) expression (Fig. 2C). The fact that these neutrophil clusters migrated with PBMC fractions on a density gradient marked them as low-density neutrophils (LDN).

In the second cohort, PBMC from 14 COVID-19 patients (7 mild, 7 severe) sampled between days 3 and 28 after onset of symptoms, and 2 controls, were collected for single-cell transcriptomic analysis using a microwell-based platform (BD Rhapsody). In total, high-quality single-cell transcriptomes for 93,297 PBMC were assessed and their overall population structure was visualized in two-dimensional space using UMAP (Fig. 2D). Data-driven cell type classification based on public reference transcriptome data (Aran et al., 2019) and cluster-specific marker gene expression depicted the presence of all major cell types expected in the PBMC compartment and revealed the appearance of additional clusters and substructures. The top 10 genes specifically expressed in each cluster of the UMAP depicted in Fig. 2D are shown in Fig. S2B. Similar to cohort 1, samples in cohort 2 also exhibited a prominent plasticity of the monocyte compartment, which could be subclassified into six clusters (Fig. 2D, cluster 1, 3, 5, 9, 12). Disease severityassociated changes seen in cohort 1 were also evident in cohort 2 (Fig. 2E). The appearance of LDN populations within the isolated PBMC fraction was validated in cohort 2, albeit at lower frequencies. Immature neutrophils and mature neutrophil cell clusters were detected in both cohorts (cluster 13 and 9 in cohort 1, cluster 18 and 13 in cohort 2) and showed a nearly identical marker gene expression profile (Fig. 2C). Similar to cohort 1, a prominent shift in subpopulation occupancy was observed in the monocyte clusters, particularly in cluster 3, 5, and 9 (Fig. 2D+E). Comparison of the specific marker genes identified for the monocyte-associated subcluster in cohort 1 with those in the corresponding cluster in cohort 2 revealed presence of the inflammatory ISG signature within the monocyte compartment, although it spread across different clusters in cohort 2 (cluster 9, 3, 1, **Fig. 2C**).

236

237

238

239240

241

242

243244245

246247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266267

268

269

270271

272

273

274

275

276

277

278

279

Single-cell transcriptomics of PBMC from COVID-19 patients identified disease-severity dependent cell subsets in the monocyte compartment as well as the appearance of two LDN populations.

Mild COVID-19 is characterized by HLA-DR+ CD11c+ monocytes with an IFN signature

The monocyte compartment is particularly affected by COVID-19, as seen by mass cytometry revealing a loss of CD14loCD16hi non-classical monocytes, particularly in mild COVID-19 (Fig. **1C+D**). Substantial shifts in monocyte subpopulation structure were also evident by scRNA-seq depending on disease severity (Fig. 2). To further dissect phenotypic alterations of the monocyte compartment in SARS-CoV-2 infection, we applied mass cytometry using a panel of 38 antibodies (**Table S2**, panel 1) to whole blood samples from COVID-19 patients with a mild or severe disease course, and corresponding age- and gender-matched healthy controls. Unsupervised cluster analysis using 15 surface antigens as well as the proliferation marker Ki67 separated the myeloid compartment into subpopulations of 'classical', 'intermediate' and 'non-classical' monocytes, myeloid dendritic cells (mDC) and plasmacytoid dendritic cells (pDC) (Fig. 3A). The classical monocyte compartment displayed a high level of heterogeneity and separated into two main subclusters. The majority of classical monocytes showed high expression of activation markers CD38, CD95, and CXCR3. Classical monocyte separated into two main subclusters based on high expression of CD62L and Ki67, indicative of proliferative capacity, versus high expression of CD226, CD69, HLA-DR and CD11c identifying highly activated, inflammatory cells (Fig. 3A). Monocytes from COVID-19 patients were clearly separated from those of healthy controls by viSNE analyses (Fig. 3B), mainly based on higher CD226 and CXCR3 expression in COVID-19 (Fig. S3A). Enhanced CD226 expression on activated monocytes might promote diapedesis through endothelial junctions and tissue infiltration, potentially explaining the relative reduction in overall monocytes in COVID-19 patients (Reymond et al., 2004). Classical monocytes in mild COVID-19 were enriched in HLA-DRhi and CD11chi populations compared to severe disease and healthy controls (Fig. S3A). Thus, the response pattern of peripheral classical monocytes to SARS-CoV-2 infection is associated with disease severity.

To investigate molecular responses of monocytes to SARS-CoV-2 infection, we extracted clusters 2, 5, 12 and 14 from the PBMC dataset of cohort 1 (**Fig. 2A**) for further in-depth analysis. Monocytes in cluster 2 particularly expressed genes found in classical monocytes, such as *VCAN* and *S100A10*, while cells in cluster 14 were characterized by high expression of *ZFP36L2*, and were hence labeled as *ZFP36L2*⁺ monocytes and classical monocytes, respectively (**Fig. 3C**). Cluster 12 was defined as non-classical monocytes by high expression of *FGR3A*, encoding CD16. As outlined before, the remaining cluster 5 (inflammatory monocytes) was characterized by an ISG program, which was further corroborated by gene ontology enrichment analysis (GOEA), assigning this cluster to 'type I interferon signaling pathway' (**Fig. 3D**). In addition,

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308 309

310

311312313

314

315316

317

318

319

320

321

322

323

inflammatory (cluster 5) and non-classical monocytes (cluster 12) were also enriched for 'MHC class II protein complex' (MHCII), which is concordant with the high expression of HLA-DRA and HLA-DRB1 in these cells (Fig. 3C, S3B). Expression of CD14 indicated that the ISG+ cells represent a population of classical monocytes (Fig. S3B). Investigation of PBMC revealed that the number of these inflammatory monocytes differed between patients with mild and severe disease courses (Fig. 2E). We next investigated this shift in greater detail in cohort 2. The dimensionality reduction and re-clustering of the monocyte space revealed high transcriptional heterogeneity within the monocyte compartment (Fig. 3E, S3D). We identified three classical monocyte clusters (cluster 0, 2, and 6), which showed high ISG expression (Fig. S3C+E). Interestingly, only cluster 2 cells co-expressed high levels of MHCII molecules (Fig. S3C) and were thereby identified as counterparts of the inflammatory monocyte cluster in cohort 1 (Fig. 3C). In contrast, the remaining two ISG+ clusters exhibited low levels of HLA-DRA and HLA-DRB1 expression (Fig. S3D), and cluster 6 was additionally characterized by platelet-associated genes (TUBB1, PPBP, and PF4) (Fig. S3E), indicating that these cells represent platelet-interacting inflammatory monocytes. Intriguingly, a proportion of cluster 0 monocytes expressed prematuration markers like MPO and PLAC8 and IL1R2, which were recently linked to an immature monocyte population found in sepsis patients (Reyes et al., 2020) (Fig. S3F). Indeed, the gene signatures derived from these sepsis-associated monocytes were specifically enriched in clusters 0 and 6 (Fig. S3G). Low HLA-DR expression and monocyte immaturity result in reduced responsiveness to microbial stimuli (Veglia et al., 2018), which is why cluster 0 cells are referred to as suppressive monocytes. To understand how the identified cell populations in the patients change over time, we next investigated the time-dependent cluster occupancies per patient in cohort 2 (Fig. 3F). This analysis clearly showed that the ISG⁺ inflammatory clusters appeared in the early phase of the disease and gradually decreased over time. In addition, the inflammatory cluster 2 was associated with patients exhibiting a mild course of the disease, whereas the suppressive cluster 0 and platelet-activated monocyte cluster 6 were associated with severe disease. The gradual decrease of the ISG+ clusters was also evident in cohort 1, which showed a clear time-dependent decrease of IFI6 and ISG15 (Fig. S3H).

Taken together, we observed dynamic changes of the monocyte compartment in SARS-CoV-2-infected patients, associated with disease severity and time after onset of disease.

Low-density neutrophils emerge in severe COVID-19 patients indicative of emergency myelopoiesis

Surprisingly, PBMC preparations in both cohorts contained two distinct clusters (**Fig. 2A**, clusters 9, 13; **Fig. 2D**, clusters 13, 18) of LDN, specifically in patients with severe disease. Since LDN in cohort 1 were more frequent than in cohort 2, we focused our in-depth analysis on cohort 1 data. We subsampled all LDN (**Fig. 4A**) and re-clustered the cells which gave rise to 8 transcriptionally distinct clusters within the LDN compartment of PBMC (**Fig. 4A+B**). We first analyzed previously described markers for pre-neutrophils, immature and mature neutrophils (Ng et al., 2019; Scapini et al., 2016) and identified cluster 4 as CD15(*FUT4*)+*CD63*+*CD66b*(*CEACAM8*)+ pre-neutrophils, clusters 3 and 6 as CD11b(*ITGAM*)+*CD101*+ immature neutrophils and the remaining clusters as

mature neutrophils (**Fig. S4A**). The identification of pre-neutrophils and immature neutrophils was further supported by signature enrichment of neutrophil progenitors derived from previous single-cell data (**Fig. 4C**) (Pellin et al., 2019; Popescu et al., 2019). Cell cycle gene analysis further corroborated cluster 4 being pre-neutrophils with the highest proportion of cells per cluster showing a proliferative signature (**Fig. S4B**). Clusters 0,1, 2 and 5 (originally from cluster 9 in **Fig. 2A**) were characterized by expression of the mature neutrophil markers *FCGR3A* (CD16) and *MME* (CD10) (**Fig. S4A**).

 Visualizing the most differentially expressed genes for each cluster revealed extensive phenotypic heterogeneity within the LDN compartment (**Fig. 4B**). For example, cluster 5 (ISG+ neutrophils) within the mature neutrophils highly expressed many ISGs (*ISG15*, *IFITM1/3* and *RSAD2*), strongly supporting an activated inflammatory neutrophil phenotype. Cluster 4 (pre-neutrophils) expressed several genes (e.g. *MPO*, *ELANE*, *PRTN3*) that have been associated with pathophysiological conditions including sepsis (Ahmad et al., 2019; Carbon et al., 2019; Silvestre-Roig et al., 2019). Similarly, immature neutrophils (clusters 3 and 6) expressed other genes (e.g. *CD24*, *LCN2*) previously associated with unfavorable outcome in sepsis (Kangelaris et al., 2015).

LDN mainly arise under pathological conditions, notably in infection and sepsis in the context of emergency myelopoiesis, and they have been associated with dysfunctional immune responses marked by combined immunosuppression and inflammation (Silvestre-Roig et al., 2019). We therefore investigated the expression of prominent genes previously linked to such pathological conditions (Fig. 4D+E). Pre-neutrophils strongly expressed PRTN3, ELANE, and MPO, genes that are involved in neutrophil extracellular trap formation (Stiel et al., 2018; Thomas et al., 2014; You et al., 2019) among other functions. Both pre-neutrophils and immature neutrophils expressed PADI4, another co-factor in NETosis (Leshner et al., 2012). NETs have recently been implicated in the pathogenesis of COVID-19 (Barnes et al., 2020; Zuo et al., 2020). Other genes, including CD24, Olfactomedin (OLFM4), Lipocalin 2 (LCN2), Bactericidal/permeability-increasing protein (BPI), previously associated with poor outcome in sepsis, were highly expressed in preand immature neutrophils (Kangelaris et al., 2015). We also observed a very strong expression of the alarmins \$100A8 and \$100A9, which is not restricted to the pre-and immature state (Fig. **4D**). Other members of the S100 gene family (e.g. S100A4, S100A12) are also strongly induced in different neutrophil clusters. Finally, known inhibitors of T cell activation, namely PD-L1 (CD274) and Arginase 1 (ARG1) (Bronte et al., 2003; Li et al., 2018) were highly expressed in neutrophils in COVID-19 patients (Fig. 4E). PD-L1⁺ mature neutrophils (clusters 0, 5) resemble cells found in HIV-1 infected patients (Bowers et al., 2014). ARG1+ cells were found among mature and immature neutrophils (clusters 1, 2, 3, 4 and 6) and did not overlap with PD-L1 expression suggesting an emergence of different populations of suppressive neutrophils in COVID-19. ARG1⁺ neutrophils in sepsis patients were shown to deplete arginine and constrain T cell function in septic shock (Darcy et al., 2014), and were predictive of the development of nosocomial infections (Uhel et al., 2017). Collectively, analyzing the LDN compartment recovered from PBMC fractions of COVID-19 patients revealed multiple mechanisms that might contribute to severe disease course and dysregulated immune responses.

Persistent increase in activated and immunosuppressive neutrophils in severe COVID-19

To further dissect the profound alterations within the neutrophil compartment, we applied mass cytometry to whole blood samples from cohort 1 and age- and gender-matched healthy controls. We specifically designed the antibody panel 2 to not only identify neutrophils but also discriminate between maturation stages and reveal phenotypical signs of activation, immunosuppressive properties or dysfunction. Unsupervised clustering analysis of all neutrophils acquired from healthy control and COVID-19 samples identified 7 major subsets (Fig. 5A). Whereas neutrophils belonging to cell subsets 2, 5 and 7 appeared quiescent, with low expression of activation markers like CD64, neutrophil subsets 1 and 6 appeared to be dominated by highly activated, CD64+, Siglec 8+, RANK+ and RANKL+ as well as Ki67+ proliferating cells. Cells within subset 3 adopted an intermediate phenotype. Neutrophils from COVID-19 patients clearly separated from those of healthy controls, and neutrophils in patients with severe COVID-19 were distinct from those of patients with mild disease (Fig. 5B). Subset 1 was highly enriched for neutrophils from COVID-19 patients. Consequently, we observed an increase in CD34⁺ immature and activated neutrophils with high CD64, Siglec 8, RANK and RANKL (Riegel et al., 2012) expression in samples from COVID-19 patients regardless of disease course (Fig. 5B+C). In contrast, CD62L was exclusively downregulated in up to 50% of the neutrophils from severe but not mild COVID-19 patients. indicative of distinct dysfunctional neutrophil populations with immunosuppressive properties (Kamp et al., 2012; Pillay et al., 2012; Tak et al., 2017). These findings were further supported by upregulation of CD123 and PD-L1 expression (Fig. 5B+C) as hallmarks of myeloid-derived suppressor cell (MDSC) function (Cassetta et al., 2019; Testa et al., 2004; Younos et al., 2015) on neutrophils of severe COVID-19 patients. In addition, neutrophils of severe COVID-19 patients adopted an aged phenotype with elevated CD45 expression (Fig. 5B).

Thus, SARS-CoV-2 infection induces major alterations in the neutrophil compartment. While neutrophils in patients with mild COVID-19 display an activated phenotype, additional markers of immunosuppression or dysfunction are upregulated in patients with severe disease.

The differences in the functional states of neutrophils in mild and severe COVID-19 in the snapshot analysis, prompted us to perform a longitudinal analysis. We analyzed samples according to collection either within the first 10 days (early) or during the second and third week (late) after onset of disease symptoms. The proportional increase in total granulocytes and CD34⁺ neutrophil subset in severe COVID-19 was only detected during the early phase of the disease (**Fig. 5D+E**). However, the additionally observed alterations in the neutrophil compartment such as loss of CD62L expression accompanied by increase of CD123 and PD-L1 positive populations as signs of dysfunctionality and immunosuppressive properties were persistent in severe COVID-19 patients (**Fig. 5E**).

Next, we analyzed whether similar to the evolution on the transcriptional level, we can also capture time-dependent changes of the monocyte compartment on the protein level. The proportion of non-classical monocytes started to recover in mild patients during the later stages of the disease (**Fig. 5D**). This was accompanied by reduced CD11c and CXCR3 expression in classical monocytes (**Fig. 5F**) and relates very well to the described longitudinal changes of the HLA-DR

& ISG+ monocyte cluster (**Fig. 3F, S3H**). In contrast, although classical monocytes of severe patients never showed high CD11c expression, they maintained high levels of CXCR3 expression even in late stages of the disease, indicating prolonged activation (**Fig. 5F**). Thus, severe COVID-19 patients are characterized by a combination of persistent inflammation and immunosuppression, which is reminiscent of long-term post-traumatic complications (Hesselink et al., 2019). Our data reveal an early strong monocyte activation versus persistent signs of neutrophil dysfunctionality as discriminators between mild and severe COVID-19.

412

413

414

415

416

417

418

419 420 421

422

423 424

425

426

427

428

429

430

431

432

433

434

435

436

437

438

439

440

441

442

443

444

445

446

447

448

449

450

451

452

453

454

455

Single cell transcriptomes of whole blood neutrophils reveal suppressive signatures in severe COVID-19

Whole blood CyTOF analysis (cohort 1) clearly indicated a very distinct molecular regulation within the neutrophil compartment in severe and mild COVID-19. To further delineate this regulation with respect to the underlying transcriptional programs, we performed scRNA-seq analysis on fresh whole blood samples from 19 individuals (21 samples, cohort 2). Overlay of all samples of cohort 2 (fresh/frozen PBMC, fresh whole blood, 162,697 cells, Fig. S6A), without batch correction, revealed the major cell type distribution, including the granulocyte compartment (Fig. 6A, S6A). Cell type distribution as identified by scRNA-seq (Fig. S6B) strongly correlated with the MCFC data of the same samples (Fig. S6C). We noticed abnormal transcriptional activation in six samples, which was caused by protracted cold treatment (4°C) prior to single-cell sampling, as recently described for PBMC (Massoni-Badosa et al., 2020). These samples were therefore excluded from further analysis. The remaining 30,019 neutrophils were subsampled and revealed a structure of 11 clusters (Fig. 6B-C). Using marker- and data-driven approaches as applied to LDN (Fig. 4D, S4A), we identified CD15(FUT4)+CD63+CD66b+CD101+CD10 preneutrophils, CD11b(ITGAM)+CD101+CD10 immature neutrophils along with 9 mature neutrophil clusters (Fig. 6B-D, S6D-E). Heterogeneous expression of various markers involved in neutrophil function including SELL (L-selectin, CD62L), CXCR2, FCGR2 (CD32), and CD10 as a marker for mature neutrophils, pointed towards distinct functionalities within the neutrophil compartment (Fig. 6C, 6H, S6E). The phenotypic diversity was further corroborated, when we assessed the expression of markers previously identified by CyTOF to be differentially regulated in patients with severe COVID-19 (Fig. 5). For example, we found elevated expression of CD274 (PD-L1) and CD64 in neutrophil clusters identified specifically in patients with severe COVID-19 (Fig. 6E, S6F). Out of the 11 neutrophil clusters identified in whole blood in cohort 2, 10 clusters could also be mapped to fresh PBMC samples in cohort 1 (Fig. S6D), indicating that scRNA-seq of fresh PBMC - in COVID-19 patients - reveals relevant parts of the neutrophil compartment. When we analyzed PBMC samples of cohort 2, these clusters could be identified in fresh samples, but were lost upon freezing (Fig. S6A). Importantly, the analysis corroborated the transcriptional phenotype of preneutrophils and immature neutrophils (cluster 8+9) in cohort 2 (Fig. 6B-D, S6D-E). Heatmap and UMAP visualization of the cell type distribution identified pre-neutrophils and immature neutrophils in severe COVID-19, at late time points (Fig. 6F-G). Furthermore, clusters 2 and 0 were associated with severe COVID-19, while clusters 5 and 10 were found in mild COVID-19 (Fig. 6F-G). IFN-signatures were detected in neutrophils from mild and severe COVID-19 patients and even in some of the clusters derived from controls (Fig. S6G). However,

expression of *CD177*, *CD274* (PD-L1) and zinc finger DHHC domain-containing palmitoyl transferases *ZDHHC19*, indicative of an immature and suppressive granulocyte phenotype (Volkmann et al., 2020), was specifically observed in patients with severe COVID-19 (**Fig. 6C**). ZDHHC19 has been shown to promote palmitoylation of STAT3 (Niu et al., 2019), as well as the Chikungunya virus derived protein nsP1 (Zhang et al., 2018). In addition, neutrophils in severe COVID-19 expressed *FCGR1A*, *ICAM1* and *ZC3H12A* (**Fig. 6H**), indicative of their suppressive nature. As indicated by the clustering in the UMAP (**Fig. 6B+G**), pseudotime analysis strongly suggested that cells in cluster 2 preceded those in cluster 0, and particularly *CD274* (PD-1L) was among the genes that further enriched in cluster 0 compared to cluster 2, indicating a progression towards a suppressive phenotype in late stage disease (**Fig. S6H+I**). Predictions of transcription factor (TF)-based regulation of the cluster-specific gene signatures revealed a strict separation of mature neutrophils from pre-neutrophils and immature neutrophils (**Fig. S6J**), but showed a surprisingly high overlap between clusters 5 (mild), 2 (severe early), and 0 (severe late) in STAT-and IRF-family member TFs (**Fig. 6I**). However, there was a striking loss of important TF hubs in cluster 0, found in late stage severe COVID-19 (**Fig. 6I**).

Collectively, the neutrophil compartment in peripheral blood of COVID-19 patients is characterized by the appearance of LDN, *ARG1*⁺*MPO*⁺*BPI*⁺ pre-neutrophils and *CD10*⁺ *S100A8/A9*⁺ immature neutrophils, reminiscent of emergency myelopoiesis, as well as *CD274*⁺(PD-L1⁺) suppressive mature neutrophils. All neutrophil subsets emerging in severe COVID-19 express an armamentarium of genes associated with suppressive functions as they have been described for sepsis or ARDS, indicating that a dysregulated myeloid cell compartment contributes to severe COVID-19.

Discussion

SARS-CoV-2 infection generally causes mild disease in the majority of individuals, however about 10-20% of COVID-19 patients progress to severe disease with pneumonia and respiratory failure. The case-fatality ratio was found to be 49% among patients with critical illness and respiratory failure (Wu and McGoogan, 2020). The pathomechanisms that govern progression from mild COVID-19 to potentially fatal courses of disease are currently unknown, but dysregulated immune responses have been repeatedly described in patients with severe COVID-19 (Zhou et al., 2020c). Detailed knowledge of the underlying molecular processes is urgently needed in order to identify predictive biomarkers and therapeutic targets for severe COVID-19, which could enable individualized treatments.

Here, we employed five complementary technologies at single-cell resolution to assess differences in the systemic immune response in patients with mild or severe courses of COVID-19. We analyzed a total of 131 samples from two independent cohorts collected at two university medical centers in Germany. The combination of single-cell transcriptomics and single-cell proteomics, using different technological platforms and sample-processing strategies in independent patient cohorts provided unprecedented insights into the systemic immune responses in COVID-19 and allowed for cross-validation of key findings.

This multipronged approach revealed drastic changes within the myeloid cell compartment, particularly in patients with a severe course of disease. Early activation of HLA-DR^{hi}CD11c^{hi} monocytes with a strong antiviral IFN-signature was a hallmark of mild COVID-19, which receded during the natural course of disease, as demonstrated at later time points in patients with mild COVID-19. In contrast, we found clear evidence of emergency myelopoiesis with release of preneutrophils and immature neutrophils with immunosuppressive features in severe COVID-19. Prolonged partial monocyte activation and release of dysfunctional neutrophils may thus contribute to severe disease course and ARDS development.

Several reports have described inflammatory monocyte responses, with a strong IFN-signature in COVID-19 (Liao et al., 2020; Merad and Martin, 2020; Zhou et al., 2020c). Mononuclear phagocytes and neutrophils appear to dominate inflammatory infiltrates in the lungs, and resident alveolar macrophages are replaced by inflammatory monocyte-derived macrophages in patients with severe COVID-19 (Liao et al., 2020). Here, we report substantial alterations of the monocyte compartment, with time- and disease severity-dependent changes in two separate cohorts of COVID-19 patients. We observed a depletion of CD14loCD16hi non-classical monocytes in all patients, which was particularly prominent in mild cases and less pronounced in severe disease (Fig. 1D). This is in line with previous reports, and it has also been observed in other severe viral infections (Lüdtke et al., 2016; Naranjo-Gómez et al., 2019). Strikingly, we found a strong transient increase in highly activated CD14+CD11chiHLA-DRhi ISG+monocytes in mild cases of COVID-19, which were absent in severe cases (Fig. 3). In contrast, we identified immature suppressive monocytes with low expression of HLA-DR in patients with severe disease. Low HLA-DR expression on monocytes has been previously associated with an increased risk to develop

infectious complications after trauma (Hoffmann et al., 2017) and increased mortality in septic shock (Monneret et al., 2006), Furthermore, CD14⁺HLA-DR^{lo/neg} monocytes, have also been identified as important mediators of tumor-induced immunosuppression (Mengos et al., 2019). Indeed, the severe COVID-19-specific immunosuppressive monocyte cluster showed enrichment of genes previously identified in sepsis patients (**Fig. S3H**) (Reyes et al., 2020).

Acute pathological insults, such as trauma or severe infections, trigger a process referred to as emergency myelopoiesis in order to replenish functional granulocytes and other hematopoietic cells. Emergency myelopoiesis is characterized by the mobilization of immature myeloid cells, which exert immunosuppressive functions (Loftus et al., 2018; Schultze et al., 2019). Emergence of suppressive myeloid cells has been previously observed during sepsis and severe influenza virus infection (Darcy et al., 2014; Loftus et al., 2018; Sander et al., 2010; De Santo et al., 2008). Here we detected pre-neutrophils and immature neutrophils within PBMC, indicating their reduced cellular density, specifically in severe COVID-19 (**Fig. 4**). These LDN showed an immature gene expression profile and a surface marker and gene expression profile indicative of immunosuppressive functions. For example, olfactomedin-4+ LDN have been associated with immunopathogenesis in sepsis (Alder et al., 2017).

Suppressive neutrophils have been shown to increase in patients with bacterial sepsis and their frequencies correlated with sepsis severity and systemic inflammation (Darcy et al., 2014), as well as in healthy volunteers treated with G-CSF (Hartung et al., 1995). Analyzing whole blood samples without density separation, we identified neutrophils with an IFN-signature in mild and severe COVID-19, but only in patients with severe disease, these activated neutrophils also expressed PD-L1 (CD274), which further increased in expression in late stage disease. The expression of CD177 on mature activated neutrophils at early stages, but not at later stages, and the identification of genes associated with suppressive cellular functions (ZDHHC19, ZC3H12A) strongly favor a model in which neutrophils emerging prematurely from the bone marrow are programmed towards a suppressive program in severe COVID-19. The transcriptional programs induced in pre-neutrophils, immature and mature COVID-19-associated neutrophil clusters may also align with other clinical observations in severe COVID-19 patients, including increased NET formation (Barnes et al., 2020; Zuo et al., 2020), coagulation (Klok et al., 2020; Pfeiler et al., 2014) and immunothrombosis (Stiel et al., 2018; Xu et al., 2020). In contrast, in patients with mild COVID-19, none of these transcriptional programs was observed. Despite the fact that SARS-CoV2^{neg} controls exhibited a range of comorbidities (e.g. COPD, type diabetes II), we did not observe this massive expansion of suppressive neutrophils in these chronic inflammatory conditions. The pathophysiological consequences of this suppressive signature in severe COVID-19 are unclear at this stage, but it is highly likely that they contribute to immunoparalysis in critically ill patients, potentially leading to insufficient host defense, disbalanced inflammation and increased susceptibility to superinfections.

Collectively, our data link a striking appearance of immature and suppressive cells, in both the monocyte and neutrophil compartment, to disease severity in COVID-19. Consequently, for the development of better treatments and prevention of severe COVID-19, we may benefit from

achievements in other fields such as cancer, which have successfully applied therapies targeting suppressive myeloid cells.

566

567

STAR Methods

Study subjects

568

569

570

579

586

587

588

589

594

595

Cohort 1 / Berlin cohort

- 571 This study includes a subset of patients enrolled between March 2 and March 27 2020 in the Pa-
- 572 COVID-19 study, a prospective observational cohort study assessing pathophysiology and clinical
- 573 characteristics of patients with COVID-19 at Charité Universitätsmedizin Berlin (Kurth et al.,
- 574 2020). The study is approved by the Institutional Review board of Charité (EA2/066/20). Written
- 575 informed consent was provided by all patients or legal representatives for participation in the
- 576 study. The patient subset included in this analysis contains 7 healthy donors (Table S1) and 19
- 577 COVID-19 patients (Figure 1A+B, Table S1). All COVID-19 patients tested positive for SARS-
- 578 CoV-2 RNA in nasopharyngeal swabs.

Cohort 2 / Bonn cohort

- This study was approved by the Institutional Review board of the University Hospital Bonn (073/19
- and 134/20). After providing written informed consent, 12 control donors (Table S1) and 14
- COVID-19 patients (Figure 1A+B, Table S1) were included in the study. In patients who were
- not able to consent at the time of study enrollment, consent was obtained after recovery. COVID-
- 19 patients who tested positive for SARS-CoV-2 RNA in nasopharyngeal swabs were recruited
- at the Medical Clinic I of the University Hospital Bonn between March 30 and May 17, 2020.

Isolation of blood cells for scRNA-seq

Cohort 1 / Berlin cohort

590 PBMC were isolated from heparinized whole blood by density centrifugation over Pancoll (density:

- 591 1.077g/ml; PAN-Biotech™). If the pellet was still slightly red, remaining CD235ab+ cells
- 592 (Erythrocytes) were depleted by Negative Selection (*MagniSort*™ Thermo Fisher). Subsequently
- the PBMC were prepared for 3'scRNA-seq (10xGenomics) or cryopreserved and analyzed later.

Cohort 2 / Bonn cohort

- In the Bonn cohort, scRNA-seq was performed on fresh whole blood, fresh PBMC and frozen
- 597 PBMC. Briefly, PBMC were isolated from EDTA-treated or heparinized peripheral blood by density
- 598 centrifugation over Pancoll or Ficoll-Paque density centrifugation (density: 1.077g/ml). Cells were
- then washed with DPBS, directly prepared for scRNA-seq (BD Rhapsody) or cryopreserved in
- 600 RPMI-1640 with 40% FBS and 10% DMSO. Whole blood was prepared by treatment of 1 ml
- 601 peripheral blood with 10 ml of RBC lysis buffer (Biolegend). After one wash in DPBS cells were
- directly processed for scRNA-seq (BD Rhapsody) or MCFC. Frozen PCMC were recovered by

rapidly thawing frozen cell suspensions in a 37° C water bath followed by immediate dilution in pre-warmed RPMI-1640+10% FBS (Gibco) and centrifugation at 300g for 5 min. After centrifugation, the cells were resuspended in RPMI-1640+10% FBS and processed for scRNA-seq. Antibody cocktails were cryopreserved as described before (Schulz et al., 2019).

Antibodies used for mass cytometry

All anti-human antibodies pre-conjugated to metal isotopes were obtained from Fluidigm Corporation (San Francisco, US). All remaining antibodies were obtained from the indicated companies as purified antibodies and in-house conjugation was done using the MaxPar X8 labeling kit (Fluidigm). Supplementary table 2 shows a detailed list of all antibodies used for panel 1 and panel 2.

Sample processing, antigen staining and data analysis of mass cytometry-based immune cell profiling

500 µl of whole blood (heparin) was fixed in 700 µl of proteomic stabilizer (Smart Tube Inc., San Carlos, US) as described in the user manual and stored at -80°C until further processing. Whole blood samples were thawed in Thaw/Lyse buffer (Smart Tube Inc.). For barcoding antibodies recognising human beta-2 microglobulin (B2M) were conjugated in house to ¹⁰⁴Pd, ¹⁰⁶Pd, ¹⁰⁸Pd, ¹¹⁰Pd, ¹⁹⁸Pt (Mei et al., 2015, 2016; Schulz and Mei, 2019). Up to 10 individual samples were stained using a staining buffer from Fluidigm with a combination of two different B2M antibodies for 30 min at 4°C. Cells were washed and pooled for surface and intracellular staining.

For surface staining the barcoded and pooled samples were equally divided into two samples. Cells were resuspended in antibody staining cocktails for panel 1 or panel 2 respectively (**Table S2**) and stained for 30 min at 4°C. For secondary antibody staining of panel 2, cells were washed and stained with anti-APC ¹⁶³Dy for 30 min at 4°C. After surface staining cells were washed with PBS, resuspended in cell-ID intercalator ¹⁰³Rh to discriminate between live and dead cells and incubated for 5 min at room temperature. After washing, cells were fixed overnight in 2 % PFA solution diluted dissolved in PBS to 2%.

For intracellular staining cells were washed twice with a permeabilization buffer (eBioscience, San Diego, US) and stained with the respective antibodies diluted in a permeabilization buffer for 30 min at room temperature. After washing, cells were stained with iridium intercalator (Fluidigm) diluted in 2 % PFA for 20 min at room temperature. Cells were washed once with PBS and then twice with ddH₂O and kept at 4°C until mass cytometry measurement.

A minimum of 100.000 cells per sample and panel were acquired on a CyTOF2/Helios mass cytometer (Fluidigm). For normalization of the fcs files 1:10 EQ Four Element Calibration Beads (Fluidigm) were added. Cells were analyzed using a CyTOF2 upgraded to Helios specifications, with software version 6.7.1014, using a narrow bore injector. The instrument was tuned according to the manufacturer's instructions with tuning solution (Fluidigm) and measurement of EQ four element calibration beads (Fluidigm) containing 140/142Ce, 151/153Eu, 165Ho and 175/176Lu served as a quality control for sensitivity and recovery. Directly prior to analysis, cells were resuspended in ddH2O, filtered through a 20-µm cell strainer (Celltrics, Sysmex), counted and adjusted to 5-8 x 105 cells/ml. EQ four element calibration beads were added at a final

concentration of 1:10 v/v of the sample volume to be able to normalize the data to compensate for signal drift and day-to-day changes in instrument sensitivity. Samples were acquired with a flow rate of 300-400 events/s. The lower convolution threshold was set to 400, with noise reduction mode turned on and cell definition parameters set at event duration of 10-150 pushes (push = 13 μ s). The resulting flow cytometry standard (FCS) files were normalized and randomized using the CyTOF software's internal FCS-Processing module on the non-randomized ('original') data. The default settings in the software were used with time interval normalization (100 s/minimum of 50 beads) and passport version 2. Intervals with less than 50 beads per 100 s were excluded from the resulting FCS file.

Blood processing for flow cytometry

1 ml of fresh blood from control or COVID-19 donors was treated with 10 ml of RBC lysis buffer (Biolegend). After RBC lysis, cells were washed with DPBS and 1-2 million cells were used for flow cytometry analysis. Cells were then stained for surface markers (**Table S3**) in DPBS with BD Horizon Brilliant™ Stain Buffer (Becton Dickinson) for 30 min at 4°C. To distinguish live from dead cells, the cells were incubated with LIVE/DEAD Fixable Yellow Dead Cell Stain Kit (1:1000 − Thermo Scientific). Following staining and washing, the cell suspension was fixed with 4% PFA for 5 min at room temperature to prevent any possible risk of contamination during acquisition of the samples. Flow cytometry analysis was performed on a BD Symphony instrument (Becton Dickinson) configured with 5 lasers (UV, violet, blue, yellow-green, red).

10x Genomics Chromium single-cell RNA-seq

PBMC were isolated and prepared as described above. Afterwards, patient samples were hashtagged with TotalSeq-A antibodies (Biolegend) according to the manufacturer's protocol for TotalSeq[™]-A antibodies and cell hashing with 10x Single Cell 3' Reagent Kit v3.1. 50 µL cell suspension with 1x106 cells were resuspended in staining buffer (2% BSA, Jackson Immuno Research; 0,01% Tween-20, Sigma-Aldrich; 1x DPBS, Gibco) and 5 µL Human TruStain FcX™ FcBlocking (Biolegend) reagent were added. The blocking was performed for 10 min at 4°C. In the next step 1 µg unique TotalSeq-A antibody was added to each sample and incubated for 30 minutes at 4°C. After the incubation time 1.5 mL staining buffer were added and centrifuged for 5 minutes at 350g and 4°C. Washing was repeated for a total of 3 washes. Subsequently, the cells were resuspended in an appropriate volume of 1x DPBS (Gibco), passed through a 40 µm mesh (FlowmiTM Cell Strainer, Merck) and counted, using a Neubauer counting (Marienfeld). Cell counts were adjusted and hashtagged cells were pooled equally. The cell suspension was super-loaded, with 50,000 cells, in the Chromium[™] Controller for partitioning single cells into nanoliter-scale Gel Bead-In-Emulsions (GEMs). Single Cell 3' reagent kit v3.1 was used for reverse transcription. cDNA amplification and library construction of the gene expression libraries (10x Genomics) following the detailed protocol provided by 10xGenomics. Hashtag libraries were prepared according to the cell hashing protocol for 10x Single Cell 3' Reagent Kit v3.1 provided by Biolegend, including primer sequences and reagent specifications. Biometra Trio Thermal Cycler was used for amplification and incubation steps (Analytik Jena). Libraries were quantified by Qubit™ 2.0 Fluorometer (ThermoFisher) and quality was checked using 2100 Bioanalyzer with High Sensitivity DNA kit (Agilent). Sequencing was performed in paired-end mode with a S1 and S2 flow cell (2 × 50 cycles kit) using NovaSeq 6000 sequencer (Illumina).

BD Rhapsody single-cell RNA-seq

688

689

690

691 692

693 694

695

696

697

698 699

700

701

702

703

704

705

706

707

708

709

710

711

712

713 714

715 716

717

718

719

720 721

722 723

724

725

726

727

728

729

Whole transcriptome analyses, using the BD Rhapsody Single-Cell Analysis System (BD, Biosciences) were performed on PBMC and whole blood samples prepared as described above. Cells from each sample were labeled with sample tags (BD™ Human Single-Cell Multiplexing Kit) following the manufacturer's protocol. Briefly, a total number of 1x106 cells were resuspended in 180µl of Stain Buffer (FBS) (BD Pharmingen). The sample tags were added to the respective samples and incubated for 20 min at room temperature. After incubation, 200µl stain buffer was added to each sample and centrifuged for 5 minutes at 300g and 4°C. Samples were washed one more time. Subsequently cells were resuspended in 300µl of cold BD Sample Buffer and counted using Improved Neubauer Hemocytometer (INCYTO). Labelled samples were pooled equally in 650µl cold BD Sample Buffer. For each pooled sample two BD Rhapsody cartridges were superloaded with approximately 60,000 cells each. Single cells were isolated using Single-Cell Capture and cDNA Synthesis with the BD Rhapsody Express Single-Cell Analysis System according to the manufacturer's recommendations (BD Biosciences). cDNA libraries were prepared using the BD Rhapsody™ Whole Transcriptome Analysis Amplification Kit following the BD Rhapsody™ System mRNA Whole Transcriptome Analysis (WTA) and Sample Tag Library Preparation Protocol (BD Biosciences). The final libraries were quantified using a Qubit Fluorometer with the Qubit dsDNA HS Kit (ThermoFisher) and the size-distribution was measured using the Agilent high sensitivity D5000 assay on a TapeStation 4200 system (Agilent technologies). Sequencing was performed in paired-end mode (2*75 cycles) on a NovaSeq 6000 and NextSeq 500 System (Illumina) with NovaSeq 6000 S2 Reagent Kit (200 cycles) and NextSeq 500/550 High Output Kit v2.5 (150 Cycles) chemistry, respectively.

Data pre-processing of 10x Genomics Chromium scRNA-seq data

CellRanger v3.1.0 (10x Genomics) was used to process scRNA-seq. To generate a digital gene expression (DGE) matrix for each sample, we mapped their reads to a combined reference of GRCh38 genome and SARS-CoV-2 genome, and recorded the number of UMIs for each gene in each cell.

Data pre-processing of BD Rhapsody scRNA-seq data

After demultiplexing of bcl files using Bcl2fastq2 V2.20 from Illumina and quality control, pairedend scRNA-seq reads were filtered for valid cell barcodes using the barcode whitelist provided by BD. Cutadapt 1.16 was then used to trim NexteraPE-PE adapter sequences where needed and to filter reads for a PHRED score of 20 or above. Then, STAR 2.6.1b was used for alignment against the Gencode v33 (GRCh38.p13) reference genome. dropseq-tools 2.0.0 were used to quantify gene expression and collapse to UMI count data. For hashtag-oligo based demultiplexing of single-cell transcriptomes and subsequent assignment of cell barcodes to their sample of origin the respective multiplexing tag sequences were added to the reference genome and quantified as well.

ScRNA-seq data analysis of 10x Chromium data of cohort 1

ScRNA-seq UMI count matrices were imported to R 3.6.2 and gene expression data analysis was performed using the R/Seurat package 3.1.4 (Butler et al., 2018; Hafemeister and Satija, 2019). Demultiplexing of cells was performed using the *HTODemux* function implemented in Seurat.

Data quality control.

We excluded the cells based on the following criteria: more than 5% mitochondrial reads, less than 200 expressed genes or more than 6000 expressed genes. We further excluded genes that were expressed in less than five cells. In addition, mitochondrial genes have been excluded from further analysis.

Data integration.

First, we SCTransformed (Seurat function) the data and then selected 2,000 features with largest variance among the data sets and identified integration anchors using these features. PCA (principal component analysis) was then performed on the integrated data sets, followed by a Shared Nearest Neighbour (SNN) Graph construction using PC1 to PC30 and for the k-Nearest Neighbours (KNN) Graph construction. The clustering analysis was performed using the Louvain algorithm with a resolution of 0.6. Uniform Manifold Approximation and Projection (UMAP) was utilized to visualize the cell clusters.

Data of control (healthy) samples were obtained from https://satijalab.org/seurat/vignettes.html and https://support.10xgenomics.com/single-cell-gene-expression/datasets/1.1.0/.

Normalization.

LogNormalization (Seurat function) was applied before downstream analysis. The original gene counts for each cell were normalized by total UMI counts, multiplied by 10,000 (TP10K) and then log transformed by log10(TP10k+1).

Differential expression tests and cluster marker genes.

Differential expression (DE) tests were performed using FindMarkers/FindAllMarkers functions in Seurat with Wilcoxon Rank Sum test. Genes with >0.25 log-fold changes, at least 25% expressed in tested groups, and Bonferroni-corrected p-values<0.05 were regarded as significantly differentially expressed genes (DEGs). Cluster marker genes were identified by applying the DE tests for upregulated genes between cells in one cluster to all other clusters in the dataset. Top ranked genes (by log-fold changes) from each cluster of interest were extracted for further illustration.

Cluster annotation.

Clusters were annotated based on a double-checking strategy: 1) by comparing cluster marker genes with public sources, and 2) by directly visualizing the expression pattern of CyTOF marker genes.

GO enrichment analysis.

Significantly differentially expressed genes (DEGs) between each monocyte cluster and the rest of monocyte subpopulations were identified by FindMarkers function from the Seurat package using Wilcoxon Rank Sum test statistics for genes expressed in at least 25% of all monocyte clusters. P-values were corrected for multiple testing using Bonferroni correction and genes with corrected P-values lower or equal 0.05 have been taken as significant DEGs for GO enrichment test by R package/ClusterProfiler v.3.10.1 (Yu et al., 2012).

Subset analysis of the neutrophils within the PBMC data set of cohort 1

The neutrophil space was investigated by subsetting the PBMC dataset to those clusters identified as neutrophils and pre-neutrophils (cluster 9 and 13). Within those subsets, we selected top 2000 variable genes and repeated a clustering using the SNN-graph based Louvain algorithm mentioned above with a resolution of 0.6. The dimensionality of the data was then reduced to 10 PCs, which served as input for the UMAP calculation. To categorize the observed neutrophil clusters into the respective cell cycle states, we applied the CellCycleScoring function of Seurat and visualized the results as pie charts.

A gene signature enrichment analysis using the 'AUCell' method (Aibar et al., 2017) was applied to link observed neutrophil clusters to existing studies and neutrophils of cohort 2. We set the threshold for the calculation of the area under the curve (AUC) to marker genes from collected publications and top 30 of the ranked maker genes from each of neutrophil clusters from cohort 2. The resulting AUC values were normalized the maximum possible AUC to 1 and subsequently visualized in violin plots or UMAP plots.

ScRNA-seq data analysis of Rhapsody data of cohort 2

General steps for Rhapsody data downstream analysis

ScRNA-seq UMI count matrices were imported to R 3.6.2 and gene expression data analysis was performed using the R/Seurat package 3.1.2 (Butler et al., 2018). Demultiplexing of cells was performed using the HTODemux function implemented in Seurat. After identification of singlets, cells with more than 25% mitochondrial reads, less than 250 expressed genes or more than 5000 expressed genes were excluded from the analysis and only those genes present in more than 5 cells were considered for downstream analysis. The following normalization, scaling and dimensionality reduction steps were performed independently for each of the data subsets used for the different analyses as indicated respectively. In general, gene expression values were normalized by total UMI counts per cell, multiplied by 10,000 (TP10K) and then log transformed by log10(TP10k+1). Subsequently, the data was scaled, centered and regressed against the number of detected genes per cell to correct for heterogeneity associated with differences in sequencing depth. For dimensionality reduction, PCA was performed on the top 2000 variable genes identified using the vst method implemented in Seurat. Subsequently, UMAP was used for two-dimensional representation of the data structure. No batch effect removal or data integration analysis was performed on the BD Rhapsody data. Cell type annotation was based on the respective clustering results combined with data-driven cell type classification algorithms based on reference transcriptomes data (Aran et al., 2019) and expression of known marker genes.

scRNA-seq analysis of the complete BD rhapsody data set of cohort 2 including data from frozen and fresh PBMC and whole blood

819 ScRNA-seq count data of 162,797 cells derived from fresh and frozen PBMC samples purified by 820 density gradient centrifugation and whole blood after erythrocyte lysis of cohort 2 (Bonn, BD 821 Rhapsody) were combined, normalized and scaled as described above. After variable gene 822 selection and PCA, UMAP was performed based on the first 25 principal components (PCs). No 823 batch correction or data integration strategies were applied to the data. Separate visualization of 824 the cells showed overlay of cells unaffected by the technical differences in sample handling. Data 825 quality and information content was visualized as violin plots showing the number of detected

826 genes and transcripts (UMIs) per sample handling strategy split by PBMC and granulocyte

827 fraction.

817

818

828

838

839

845

846

847

848

849

850

851

852

853

854

scRNA-seg analysis of fresh and frozen PBMC samples

829 ScRNA-seg count data of 93,297 cells derived from fresh and frozen PBMC samples of cohort 2 830 (Bonn, BD Rhapsody) purified by density gradient centrifugation were normalized and scaled as 831 described above. After variable gene selection and PCA, UMAP was performed and the cells 832 were clustered using the Louvain algorithm based on the first 15 PCs and a resolution of 0.5. 833 Cluster identities were determined by reference-based cell classification and inference of cluster-834 specific marker genes using the Wilcoxon rank sum test using the following cutoffs: genes have 835 to be expressed in more than 20% of the cells of the respective cluster, exceed a logarithmic 836 fold change cutoff to at least 0.25, and exhibited a difference of > 10% in the detection between 837 two clusters.

Quantification of the percentages of cell clusters in the PBMC scRNA-seg data of both cohorts separated by disease group

840 To compare shifts in the monocyte and neutrophil populations in the PBMC compartment of 841 COVID-19 patients, the percentages of the cellular subsets - as identified by clustering and cluster 842 annotation explained above for the two independent scRNA-seq data sets (cohort 1 and cohort 843 2) - of the total number of PBMC in each data set were quantified per sample and visualized 844 together in box plots. Statistical significance was inferred using *t*-test.

Subset analysis of the monocytes within the PBMC data set of cohort 2

The monocyte space was investigated by subsetting the PBMC dataset to those clusters identified as monocytes (cluster 1, 3, 5, 9, and 12) and repeating the variable gene selection (top 2000 variable genes), regression for the number of UMIs and scaling as described above. The dimensionality of the data was then reduced to 8 PCs, which served as input for the UMAP calculation. The SNN-graph based Louvain clustering of the monocytes was performed using a resolution of 0.48. Marker genes per cluster were calculated using the Wilcoxon rank sum test using the following cutoffs: genes have to be expressed in > 20% of the cells, exceed a logarithmic fold change cutoff to at least 0.25, and exhibited a difference of > 10% in the detection

between two clusters.

Time kinetics analysis of identified monocyte clusters

855

856

857

858

859

860

861 862

863

864

865

866

867

868

869

870

871

872

873

874

875

876

877

878

879

880

881

882

883

884

885

886

892

For each patient and time point of sample collection, the proportional occupancy of the monocyte clusters was calculated, and the relative proportions were subsequently visualized as a function of time.

Analysis of the scRNA-seq data from fresh PBMC and whole blood samples of cohort 2

ScRNA-seq count data derived from fresh PBMC samples purified by density gradient centrifugation and whole blood after erythrocyte lysis of cohort 2 (BD Rhapsody) were normalized, scaled, and regressed for the number of UMI per cell as described above. After PCA based on the top 2000 variable genes, UMAP was performed using the first 15 PCs. Cell clusters were determined using Louvain clustering implemented in Seurat based on the first 15 principle components and a resolution of 0.5. Cluster identities were assigned as detailed above using reference-based classification and marker gene expression. Subsequently, the dataset was subsetted for clusters identified as neutrophils and pre-neutrophils, and re-scaled and regressed. After PCA on the top 2000 variable genes, UMAP was performed on the first 15 PCs. Clustering was performed as described above on the top 15 PCs using a resolution of 0.5. Clusters featuring high counts in hemoglobin genes and expression of the eosinophil specific marker gene CLC were excluded from subsequent analyses. After filtering and rescaling of the neutrophil compartment a division of the cells according to experimental batches was observed in the two-dimensional UMAP representation. Comparing experimental procedures of different experiments pointed to short-term storage of whole blood on ice for a single experimental batch as a technical influence potentially explaining the transcriptional differences. Therefore, cells from the respective experiment were excluded, reducing the number of samples to a total of 15 (30,019 cells, 10 controls, 5 COVID-19 patients) to prevent any technical bias from skewing the analysis. After exclusion, the remaining data were processed as described above and clustered using Louvain clustering based on the first 15 PCs with a resolution of 0.7 was performed.

Differentially expressed genes between clusters were defined using a Wilcoxon rank sum test for differential gene expression implemented in Seurat. Genes had to be expressed in >10% of the cells of a cluster, exceed a logarithmic threshold >0.1 and to have >10% difference in the minimum detection between two clusters.

Quantification of the percentages of cell subsets in the fresh whole blood scRNA-seq data of cohort 2

After cell type classification of the combined scRNA-seq data set of fresh PBMC and whole blood samples of cohort 2 described above, 69.500 cells derived from whole blood samples after erythrocyte lysis were subsetted. Percentages of cell subsets in those whole blood samples of the total number of cells were quantified per sample and visualized r in box plots separated by disease stage and group.

Confusion matrix

- 893 For each cluster of neutrophils, the relative proportion across disease severity and time point was
- visualized as a fraction of samples from the respective condition contributing to the cluster.

895 **GO enrichment**

900

903

916

926

- 896 Gene set enrichment was performed on gene sets from the Kyoto Encyclopedia of Genes and
- 897 Genomes (KEGG) database (Kanehisa, 2019), Hallmark gene sets (Liberzon et al., 2015) and
- 898 Gene Ontology (GO) (Ashburner et al., 2000; Carbon et al., 2019) using the R
- 899 package/ClusterProfiler v.3.10.1 (Yu et al., 2012).

Cell cycle state analysis of scRNA-Seq data

- 901 To categorize the cells within the neutrophil clusters into the respective cell cycle states, we
- applied the *CellCycleScoring* function of Seurat and visualized the results as pie charts.

Trajectory analysis

- Trajectory analysis was performed using the destiny algorithm (Angerer et al., 2016). In brief, the
- 905 neutrophil space was subsetted to only severe patients (early and mild) and only the most
- 906 prominent clusters of the latter (clusters 9,8,2,0,6). The normalized data were scaled and
- 907 regressed for UMIs and a diffusion map was calculated based on the top 2.000 variable genes
- 908 with a sum of at least 10 counts over all cells. Based on the diffusion map, a diffusion pseudo
- 909 time was calculated (without fixing a starting point) to infer a transition probability between the
- 910 different cell states of the neutrophils. Subsequently, the density of the clusters along the
- 911 pseudotime and marker gene expression for each cluster were visualized.
- 912 Enrichment of gene sets was performed using the 'AUCell' method (Aibar et al., 2017)
- 913 implemented in the package (version 1.4.1) in R. We set the threshold for the calculation of the
- 914 AUC to the top 3% of the ranked genes and normalized the maximum possible AUC to 1. The
- 915 resulting AUC values were subsequently visualized in violin plots or UMAP plots.

Transcription factor prediction analysis

- 917 The Cytoscape (version v3.7.1, doi: 10.1101/gr.1239303) plug-in iRegulon (Janky et al., 2014)
- 918 (version 1.3) was used to predict the transcription factors potentially regulating cluster-specifically
- 919 expressed gene sets in the neutrophil subset analysis in cohort 2. The genomic regions for TF-
- 920 motif search were limited to 10 kbp around the respective transcriptional start sites and filtered
- 921 for predicted TFs with a normalized enrichment score > 4.0. Next, we filtered for TFs, which
- 922 exceeded a cumulative normalized expression cutoff of 50 in the respective neutrophil cluster.
- 923 Subsequently, we selected transcription factors of known relevance in the context of neutrophil
- 924 biology and constructed a network linking target genes among the cluster-specifically expressed
- marker genes and their predicted and expressed regulators for visualization in Cytoscape.

Mass cytometry data analysis

- Cytobank.org was used for de-barcoding of individual samples and manually gating of cell events to remove doublets, normalization beads and dead cells (Kotecha et al., 2010). For semi-automated gating of populations of interest, high-resolution SPADE clustering was conducted on all indicated markers (supplementary table 2) with 400 target nodes. Individual SPADE nodes were then aggregated and annotated to cell subsets (bubbles) according to the expression of lineage-specific differentiation markers.
- To generate tSNE maps viSNE analysis was performed using the indicated markers (supplementary table 2). Embedding parameters were set to at least 1000 iterations per 100.000 analyzed cells, perplexity of 30 and theta of 0.5. For statistical analysis of cell population abundances, we fitted a generalized linear mixed-effects model (GLMM) for each population the lme4 package as previously described by Nowicka et. al (Robinson et al., 2017).

Data Analysis of Flow Cytometry Data

- 939 Flow cytometry data analysis was performed with FlowJo V10.6.1. Relative cell percentage or
- 940 mean fluorescence intensity (MFI) was used for visualization and statistical analysis. Cell type
- was defined as granulocytes (CD45⁺, CD66b⁺), non-classical monocytes (CD45⁺, CD66b⁻, CD19⁻
- 942 , CD3⁻, CD56⁻, CD14^{dim}, CD16⁺).

Data visualization

- In general, the R packages Seurat and the ggplot2 package (version 3.1.0, Wickham, 2016) were
- 945 used to generate figures. For visualization of mass cytometry data, cluster minimum-spanning
- trees were rendered using Cytobank, the ComplexHeatmap package was used to display subset
- 947 phenotypes and GraphPad Prism to generate boxplots of quantitative data.

948 **Lead Contact**

938

943

954

- 949 Further information and requests for resources and reagents should be directed to the Lead
- 950 Contact, Joachim L. Schultze

951 **Data Availability**

- 952 Data are deposited at the European Genome-phenome Archive (EGA) under access number
- 953 EGAS00001004450, which is hosted by the EBI and the CRG.

KEY RESOURCES TABLE

955

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Antibodies		•
HLA-DR BV421 (L243)	Biolegend	307635 (AB_10897449)
CD4 BV510 (OKT4)	Biolegend	317444 (AB_2561866)
CD16 BV605 (3G8)	Biolegend	302039 (AB_2561354)
CD45 BV711 (HI30)	Biolegend	304050 (AB_2563466)
CD8 BV785 (SK1)	Biolegend	344740 (AB_2566202)
CD66b FITC (G10F5)	Biolegend	305104 (AB_314496)
CD14 PerCp-Cy5.5 (MφP9)	Becton Dickinson	562692 (AB_2737726)
CD56 PE (MY31)	Becton Dickinson	345810 (AB_396511)
CD3 PE/Dazzle (UCHT1)	Biolegend	300450 (AB_2563618)
CD11c PE/Cy5 (B-ly6)	Becton Dickinson	551077 (AB_394034)
Siglec8 PE/Cy7 (7C9)	Biolegend	347112 (AB_2629720)
CD203c APC (NP4D6)	Biolegend	324609 (AB_2099774)
CD1c AlexaFluor700 (L161)	Biolegend	331530 (AB_2563657)
CD19 APC/Fire 750 (HIB19)	Biolegend	302258 (AB_2629691)
CD45 89Y (HI30)	Fluidigm	3089003B

HLADR purified (L243)	Biolegend	307602
CD3 purified (UCHT1)	Biolegend	300443
CD196 141Pr (G034E3)	Fluidigm	3141003A
CD19 142Nd (HIB-19)	Fluidigm	3142001B
CD123 143Nd (6H6)	Fluidigm	3143014B
CD15 144Nd (W6D3)	Fluidigm	3144019B
CD138 145Nd (DL101)	Fluidigm	3145003B
CD64 146Nd (10.1)	Fluidigm	3146006B
CD21 purified (Bu32)	Biolegend	354902
CD226 purified (REA1040)	Miltenyi Biotec	Produced at request
IgD purified (IgD26)	Biolegend	348235
ICOS 148Nd (C398.4A)	Fluidigm	3148019B
CD206 purified (152)	Biolegend	321127
CD96 purified (REA195)	Miltenyi Biotec	Produced at request
KLRG1 purified (REA261)	Miltenyi Biotec	Produced at request
TCRgd purified (11F2)	Miltenyi Biotec	Produced at request
FcɛRI 150Nd (AER-37)	Fluidigm	3150027B
CD155 purified (REA1081)	Miltenyi Biotec	Produced at request
CD95 purified (DX2)	Biolegend	305631

TIGIT 153Eu (MBSA43)	Fluidigm	3153019B
CD62L 153Eu (DREG56)	Fluidigm	3153004B
CD62L purified (DREG56)	Biolegend	304835
CD1c purified (L161)	Biolegend	331502
CD27 155Gd (L128)	Fluidigm	3155001B
CXCR3 156Gd (G025H7)	Fluidigm	3156004B
KLRF1 purified (REA845)	Miltenyi Biotec	Produced at request
CD10 158Gd (HI10a)	Fluidigm	3158011B
CD33 158Gd (WM53)	Fluidigm	3158001B
CD14 160Gd (RMO52)	Fluidigm	3160006B
CD28 purified (L293)	BD Bioscience	348040
CD69 162Dy (FN50)	Fluidigm	3162001B
CD294 163Dy (BM16)	Fluidigm	3163003B
RANKL APC	Miltenyi Biotec	130-098-511
Anti-APC 163Dy	Fluidigm	3163001B
CXCR5 164Dy (51505)	Fluidigm	3164029B
Siglec 8 164Dy (7C9)	Fluidigm	3164017B
CD34 166Er (581)	Fluidigm	3166012B
CD38 167Er (HIT2)	Fluidigm	3167001B

Ki67 168Er (Ki-67)	Fluidigm	3168007B
CD25 169Tm (2A3)	Fluidigm	3169003B
CD24 169Tm (ML5)	Fluidigm	3169004B
Lag3 purified (11C3C65)	Biolegend	369302
RANK purified (80704)	R&D Systems	MAB683
CD161 purified (HP-3G10)	Biolegend	339919
CD11b purified (ICRF44)	Biolegend	301337
CD45RO purified (4G11)	DRFZ Berlin	
CD44 purified (BJ18)	Biolegend	338811
CD137 173Yb (4B4-1)	Fluidigm	3173015B
PD-1 175Lu (EH12.2H7)	Fluidigm	3175008B
PD-L1 175Lu (29.E2A3)	Fluidigm	3175017B
CD56 176Yb (NCAM16.2)	Fluidigm	3176008B
CD8A purified (GN11)	DRFZ Berlin	
IgM purified (MHM-88)	Biolegend	314502
CD11c purified (Bu15)	Biolegend	337221
B2M purified (2M2)	Biolegend	316302
CD16 209Bi (3G8)	Fluidigm	3209002B
A0251 anti-human Hashtag 1	Biolegend	394601

	•	,
A0252 anti-human Hashtag 2	Biolegend	394603
A0253 anti-human Hashtag 3	Biolegend	394605
A0254 anti-human Hashtag 4	Biolegend	394607
A0255 anti-human Hashtag 5	Biolegend	394609
A0256 anti-human Hashtag 6	Biolegend	394611
A0257 anti-human Hashtag 7	Biolegend	394613
CD235ab Biotin (HIR2)	Biolegend	306618
Bacterial and Virus Strains		
Biological Samples		
Chemicals, Peptides, and Recombinant Prot	eins	
BD Horizon Brilliant™ Stain Buffer	Becton Dickinson	563794
RBC lysis buffer 10X	Biolegend	420301
Pierce™ 16% Formaldehyde (w/v), Methanol-free	Thermo Fisher	28908
RPMI 1640 Medium	Gibco	11875093
Fetal Bovine Serum	PAN Biotec	3302

Stain Buffer (FBS)	Becton Dickinson	554656
Pancoll human, Density: 1.077 g/ml	Pan Biotech	P04-601000
Dulbecco'S Phosphate Buffered Saline, MO	Sigma-Aldrich	D8537
FcR Blocking Reagent, human	Miltenyi	130-059-901
Live/Dead mDOTA 103Rh	In-house	
Cell-ID Intercalator-Ir	Fluidigm	201192A
Permeabilization buffer 10X	eBioscience	00-8333-56
Maxpar PBS	Fluidigm	201058
Maxpar Cell Staining buffer	Fluidigm	201068
Maxpar X8 Multimetal Labeling Kit	Fluidigm	201300
Proteomic stabilizer	Smart Tube Inc.	PROT1
Nuclease-Free Water	Invitrogen	AM9937
KAPA HiFi HotStart Ready Mix	Roche	KK2601
Human Tru Stain FcX	Biolegend	422301
TE Buffer	Thermo Fisher	120900115
SPRIselect Reagent	Invitrogen	AM9937
10% Tween 20	BIO-RAD	1662404
Buffer EB	Qiagen	19086
Ethanol, Absolute	Fisher Bioreagents	BP2818-500

Glycerol, 85%	Merck	1040941000
Bovine Serum Albumin	Jackson Immuno Research	001-000-161
Tween20	Sigma-Aldrich	P1379-500M
MagniSort™ Negative Selection Beads	Thermo Fisher	MSNB-6002-74
Critical Commercial Assays		
LIVE/DEAD Fixable Yellow Dead Cell Stain Kit	Thermo Fisher	L34967
Human Single-Cell Multiplexing Kit	BD	633781
BD Rhapsody™ WTA Amplification Kit	BD	633801
BD Rhapsody Cartridge Kit	BD	633733
BD Rhapsody cDNA Kit	BD	633773
High Sensitivity D5000 ScreenTape	Agilent	5067-5592
Qubit dsDNA HS Assay Kit	ThermoFisher	Q32854
Chromium Next GEM Single Cell 3' GEM, Library & Gel Bead Kit v3.1	10x genomics	1000121
Chromium Next GEM Chip G Single Cell Kit	10x genomics	1000120
Single Index Kit T Set A	10x genomics	1000213
High Sensitivity DNA Kit	Agilent	5067-4626
NovaSeq 6000 S1 Reagent Kit (100 cycle)	Illumina	200012865
NovaSeq 6000 S2 Reagent Kit (100 cycle)	Illumina	20012862

NovaSeq 6000 S2 Reagent Kit (200 cycles)	Illumina	20040326
NovaSeq 6000 S2 Reagent Kit (200 cycles)	Illumina	20040326
NextSeq 500/550 High Output Kit v2.5 (150 Cycles)	Illumina	20024907
Deposited Data	Į.	
RNA-Seq raw data	This paper	EGAS00001004450
Experimental Models: Cell Lines		
Experimental Models: Organisms/Strains		
Oligonucleotides		
SI-PCR primer	IDT	AATGATACGGCG ACCACCGAGATC TACACTACACTCT TTCCCTACACGAC GC*T*C
HTO additive primer	IDT	GTGACTGGAGTT CAGACGTGTGC*T *C
D701_S	IDT	CAAGCAGAAGAC GGCATACGAGAT CGAGTAATGTGA CTGGAGTTCAGA CGTGT*G*C

D702_S	IDT	CAAGCAGAAGAC GGCATACGAGAT TCTCCGGAGTGA CTGGAGTTCAGA CGTGT*G*C	
D703_S	IDT	CAAGCAGAAGAC GGCATACGAGAT AATGAGCGGTGA CTGGAGTTCAGA CGTGT*G*C	
D705_S	IDT	CAAGCAGAAGAC GGCATACGAGAT TTCTGAATGTGAC TGGAGTTCAGAC GTGT*G*C	
Recombinant DNA			
Software and Algorithms			
Seurat (R package)	CRAN	v3.1.4	
Seurat (R package)	CRAN	v3.1.2	
ClusterProfiler (R package)	CRAN	v3.10.1	
DirichletReg (R package)	CRAN	v0.6.3.1	
AUCell (R package)	CRAN	v1.6.1	
Cytobank (software)	Kotecha N, et al., Curr Protoc Cytom. 2010	https://doi.org/10.10 02/0471142956.cy1 017s53	

	https://www.cytoban k.org	
SPADE (Cytobank)	Qiu P, et al., Nat Biotechnol. 2011	https://doi.org/10.10 38/nbt.1991
viSNE (Cytobank)	Amir el-AD, et al., Nat Biotechnol. 2013	https://doi.org/10.10 38/nbt.2594
flowCore (R package)	Bioconductor	v1.48.1
CytoML (R package)	Bioconductor	v1.8.1
flowFP (R package)	Bioconductor	v1.40.1
ComplexHeatmap (R package)	Bioconductor	v1.20.0
Ime4 (R package)	CRAN	v1.1-21
Prism (software)	www.graphpad.com	v8
Other	-	

References

- 958 Ahmad, S., Singh, P., Sharma, A., Arora, S., Shriwash, N., Rahmani, A.H., Almatroodi, S.A., 959 Manda, K., Dohare, R., and Syed, M.A. (2019). Transcriptome meta-analysis deciphers a 960 dysregulation in immune response-associated gene signatures during sepsis. Genes (Basel).
- 961 *10*, 1005.

- Aibar, S., González-Blas, C.B., Moerman, T., Huynh-Thu, V.A., Imrichova, H., Hulselmans, G., Rambow, F., Marine, J.C., Geurts, P., Aerts, J., et al. (2017). SCENIC: Single-cell regulatory network inference and clustering. Nat. Methods *14*, 1083–1086.
- Alder, M.N., Opoka, A.M., Lahni, P., Hildeman, D.A., and Wong, H.R. (2017). Olfactomedin-4 Is a Candidate Marker for a Pathogenic Neutrophil Subset in Septic Shock. Crit. Care Med. *45*, e426–e432.
- Allan, R.P., Barlow, M., Byrne, M.P., Cherchi, A., Douville, H., Fowler, H.J., Gan, T.Y., Pendergrass, A.G., Rosenfeld, D., Swann, A.L.S., et al. (2020). Advances in understanding large-scale responses of the water cycle to climate change. Ann. N. Y. Acad. Sci.
- 971 Angerer, P., Haghverdi, L., Büttner, M., Theis, F.J., Marr, C., and Buettner, F. (2016). Destiny: Diffusion maps for large-scale single-cell data in R. Bioinformatics *32*, 1241–1243.
- 973 Aran, D., Looney, A.P., Liu, L., Wu, E., Fong, V., Hsu, A., Chak, S., Naikawadi, R.P., Wolters, P.J., Abate, A.R., et al. (2019). Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage. Nat. Immunol. *20*, 163–172.
- Ashburner, M., Ball, C.A., Blake, J.A., Botstein, D., Butler, H., Cherry, J.M., Davis, A.P., Dolinski, K., Dwight, S.S., Eppig, J.T., et al. (2000). Gene ontology: Tool for the unification of biology. Nat. Genet. *25*, 25–29.
- Barnes, B.J., Adrover, J.M., Baxter-Stoltzfus, A., Borczuk, A., Cools-Lartigue, J., Crawford, J.M.,
 Daßler-Plenker, J., Guerci, P., Huynh, C., Knight, J.S., et al. (2020). Targeting potential drivers
 of COVID-19: Neutrophil extracellular traps. J. Exp. Med. 217.
- Bowers, N.L., Helton, E.S., Huijbregts, R.P.H., Goepfert, P.A., Heath, S.L., and Hel, Z. (2014).
 Immune Suppression by Neutrophils in HIV-1 Infection: Role of PD-L1/PD-1 Pathway. PLoS Pathog. 10.
- 985 Braun, J., Loyal, L., Frentsch, M., Wendisch, D., Georg, P., Kurth, F., Hippenstiel, S., Dingeldey, M., Kruse, B., Fauchere, F., et al. (2020). Presence of SARS-CoV-2 reactive T cells in COVID-19 patients and healthy donors. MedRxiv 2020.04.17.20061440.
- 988 Brignola, C., Campieri, M., Farruggia, P., Tragnone, A., Pasquali, S., Iannone, P., Lanfranchi, 989 G.A., and Barbara, L. (1988). The possible utility of steroids in the prevention of relapses of crohn's disease in remission: A preliminary study. J. Clin. Gastroenterol. *10*, 631–634.
- 991 Bronte, V., Serafini, P., Mazzoni, A., Segal, D.M., and Zanovello, P. (2003). L-arginine metabolism in myeloid cells controls T-lymphocyte functions. Trends Immunol. *24*, 301–305.
- 993 Butler, A., Hoffman, P., Smibert, P., Papalexi, E., and Satija, R. (2018). Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat. Biotechnol. *36*, 411–420.
- Carbon, S., Douglass, E., Dunn, N., Good, B., Harris, N.L., Lewis, S.E., Mungall, C.J., Basu, S., Chisholm, R.L., Dodson, R.J., et al. (2019). The Gene Ontology Resource: 20 years and still GOing strong. Nucleic Acids Res. *47*, D330–D338.
- 999 Cassetta, L., Baekkevold, E.S., Brandau, S., Bujko, A., Cassatella, M.A., Dorhoi, A., Krieg, C., Lin, A., Loré, K., Marini, O., et al. (2019). Deciphering myeloid-derived suppressor cells: isolation
- and markers in humans, mice and non-human primates. Cancer Immunol. Immunother. 68,
- 1002 687–697.

- 1003 Chen, G., Wu, D., Guo, W., Cao, Y., Huang, D., Wang, H., Wang, T., Zhang, X., Chen, H., Yu,
- H., et al. (2020). Clinical and immunologic features in severe and moderate Coronavirus Disease
- 1005 2019. J. Clin. Invest.
- Darcy, C.J., Minigo, G., Piera, K.A., Davis, J.S., McNeil, Y.R., Chen, Y., Volkheimer, A.D.,
- 1007 Weinberg, J.B., Anstey, N.M., and Woodberry, T. (2014). Neutrophils with myeloid derived
- suppressor function deplete arginine and constrain T cell function in septic shock patients. Crit.
- 1009 Care 18, R163.
- Dimopoulos, G., de Mast, Q., Markou, N., Theodorakopoulou, M., Komnos, A., Mouktaroudi, M.,
- Netea, M.G., Spyridopoulos, T., Verheggen, R.J., Hoogerwerf, J., et al. (2020). FAVORABLE
- 1012 ANAKINRA RESPONSES IN SEVERE COVID-19 PATIENTS WITH SECONDARY
- 1013 HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS. Cell Host Microbe.
- 1014 Fauver, J.R., Petrone, M.E., Hodcroft, E.B., Shioda, K., Ehrlich, H.Y., Watts, A.G., Vogels, C.B.F.,
- Brito, A.F., Alpert, T., Muyombwe, A., et al. (2020). Coast-to-Coast Spread of SARS-CoV-2
- during the Early Epidemic in the United States. Cell.
- 1017 Giamarellos-Bourboulis, E.J., Netea, M.G., Rovina, N., Akinosoglou, K., Antoniadou, A.,
- 1018 Antonakos, N., Damoraki, G., Gkavogianni, T., Adami, M.E., Katsaounou, P., et al. (2020).
- 1019 Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure. Cell
- 1020 Host Microbe.
- 1021 Grifoni, A., Weiskopf, D., Ramirez, S.I., Mateus, J., Dan, J.M., Moderbacher, C.R., Rawlings, S.A.,
- Sutherland, A., Premkumar, L., Jadi, R.S., et al. (2020). Targets of T cell responses to SARS-
- 1023 CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell.
- 1024 Guan, W.J., Ni, Z.Y., Hu, Y., Liang, W.H., Ou, C.Q., He, J.X., Liu, L., Shan, H., Lei, C.L., Hui,
- D.S.C., et al. (2020a). Clinical Characteristics of Coronavirus Disease 2019 in China. N. Engl.
- 1026 J. Med.
- 1027 Guan, W.J., Liang, W.H., Zhao, Y., Liang, H.R., Chen, Z.S., Li, Y.M., Liu, X.Q., Chen, R.C., Tang,
- 1028 C.L., Wang, T., et al. (2020b). Comorbidity and its impact on 1590 patients with Covid-19 in
- 1029 China: A Nationwide Analysis. Eur. Respir. J.
- Hadjadj, J., Yatim, N., Barnabei, L., Corneau, A., Boussier, J., Pere, H., Charbit, B., Bondet, V.,
- 1031 Chenevier-Gobeaux, C., Breillat, P., et al. (2020). Impaired type I interferon activity and
- 1032 exacerbated inflammatory responses in severe Covid-19 patients. MedRxiv
- 1033 2020.04.19.20068015.
- Hafemeister, C., and Satija, R. (2019). Normalization and variance stabilization of single-cell
- 1035 RNA-seq data using regularized negative binomial regression. Genome Biol. 20.
- 1036 Hartung, T., Döcke, W.D., Gantner, F., Krieger, G., Sauer, A., Stevens, P., Volk, H.D., and
- 1037 Wendel, A. (1995). Effect of granulocyte colony-stimulating factor treatment on ex vivo blood
- 1038 cytokine response in human volunteers. Blood 85, 2482–2489.
- 1039 Hesselink, L., Spijkerman, R., Van Wessem, K.J.P., Koenderman, L., Leenen, L.P.H., Huber-
- Lang, M., and Hietbrink, F. (2019). Neutrophil heterogeneity and its role in infectious
- 1041 complications after severe trauma. World J. Emerg. Surg. 14.
- Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens,
- T.S., Herrler, G., Wu, N.H., Nitsche, A., et al. (2020). SARS-CoV-2 Cell Entry Depends on ACE2
- and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell 181, 271-280.e8.
- Hoffmann, S., Harms, H., Ulm, L., Nabavi, D.G., Mackert, B.M., Schmehl, I., Jungehulsing, G.J.,
- 1046 Montaner, J., Bustamante, A., Hermans, M., et al. (2017). Stroke-induced immunodepression
- and dysphagia independently predict stroke-associated pneumonia The PREDICT study. J.
- 1048 Cereb. Blood Flow Metab. 37, 3671–3682.
- 1049 Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al.

- 1050 (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395, 497–506.
- Jamilloux, Y., Henry, T., Belot, A., Viel, S., Fauter, M., El Jammal, T., Walzer, T., François, B., and Sève, P. (2020). Should we stimulate or suppress immune responses in COVID-19?
- 1054 Cytokine and anti-cytokine interventions. Autoimmun. Rev. 102567.
- Kamp, V.M., Pillay, J., Lammers, J.-W.J., Pickkers, P., Ulfman, L.H., and Koenderman, L. (2012).
- Human suppressive neutrophils CD16 bright /CD62L dim exhibit decreased adhesion . J. Leukoc. Biol. *92*, 1011–1020.
- Kanehisa, M. (2019). Toward understanding the origin and evolution of cellular organisms. Protein Sci. 28, 1947–1951.
- Kangelaris, K.N., Prakash, A., Liu, K.D., Aouizerat, B., Woodruff, P.G., Erle, D.J., Rogers, A., Seeley, E.J., Chu, J., Liu, T., et al. (2015). Increased expression of neutrophil-related genes in
- patients with early sepsis-induced ARDS. Am. J. Physiol. Lung Cell. Mol. Physiol. 308, L1102–
- 1063 L1113.
- Klok, F.A., Kruip, M.J.H.A., van der Meer, N.J.M., Arbous, M.S., Gommers, D.A.M.P.J., Kant, K.M., Kaptein, F.H.J., van Paassen, J., Stals, M.A.M., Huisman, M. V., et al. (2020). Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb. Res.
- 1067 Kotecha, N., Krutzik, P.O., and Irish, J.M. (2010). Web-based analysis and publication of flow
- 1068 cytometry experiments. Curr. Protoc. Cytom.
- Kurth, F., Roennefarth, M., Thibeault, C., Corman, V.M., Mueller-Redetzky, H., Mittermaier, M., Ruwwe-Gloesenkamp, C., Krannich, A., Schmidt, S., Kretzler, L., et al. (2020). Studying the
- pathophysiology of coronavirus disease 2019 a protocol for the Berlin prospective COVID-19
- 1072 patient cohort (Pa- COVID-19). MedRxiv 2020.05.06.20092833.
- 1073 Kverneland, A.H., Streitz, M., Geissler, E., Hutchinson, J., Vogt, K., Boës, D., Niemann, N.,
- 1074 Pedersen, A.E., Schlickeiser, S., and Sawitzki, B. (2016). Age and gender leucocytes variances
- and references values generated using the standardized ONE-Study protocol. Cytom. Part A 89, 543–564.
- Leshner, M., Wang, S., Lewis, C., Zheng, H., Chen, X.A., Santy, L., and Wang, Y. (2012). PAD4
 mediated histone hypercitrullination induces heterochromatin decondensation and chromatin
- unfolding to form neutrophil extracellular trap-like structures. Front. Immunol. 3.
- Li, W., Moore, M.J., Vasllieva, N., Sui, J., Wong, S.K., Berne, M.A., Somasundaran, M., Sullivan, J.L., Luzuriaga, K., Greeneugh, T.C., et al. (2003). Angiotensin-converting enzyme 2 is a
- functional receptor for the SARS coronavirus. Nature 426, 450–454.
- Li, X.K., Lu, Q. Bin, Chen, W.W., Xu, W., Liu, R., Zhang, S.F., Du, J., Li, H., Yao, K., Zhai, D., et al. (2018). Arginine deficiency is involved in thrombocytopenia and immunosuppression in
- severe fever with thrombocytopenia syndrome. Sci. Transl. Med. 10.
- 1086 Liao, M., Liu, Y., Yuan, J., Wen, Y., Xu, G., Zhao, J., Chen, L., Li, J., Wang, X., Wang, F., et al.
- 1087 (2020). The landscape of lung bronchoalveolar immune cells in COVID-19 revealed by singlecell RNA sequencing. MedRxiv 2020.02.23.20026690.
- Liberzon, A., Birger, C., Thorvaldsdóttir, H., Ghandi, M., Mesirov, J.P., and Tamayo, P. (2015).
- The Molecular Signatures Database Hallmark Gene Set Collection. Cell Syst. *1*, 417–425.
- Loftus, T.J., Mohr, A.M., and Moldawer, L.L. (2018). Dysregulated myelopoiesis and hematopoietic function following acute physiologic insult. Curr. Opin. Hematol. *25*, 37–43.
- 1093 Long, Q.-X., Liu, B.-Z., Deng, H.-J., Wu, G.-C., Deng, K., Chen, Y.-K., Liao, P., Qiu, J.-F., Lin, Y.,
- Cai, X.-F., et al. (2020). Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat.
- 1095 Med. 1–4.
- 1096 Lüdtke, A., Ruibal, P., Becker-Ziaja, B., Rottstegge, M., Wozniak, D.M., Cabeza-Cabrerizo, M.,

- 1097 Thorenz, A., Weller, R., Kerber, R., Idoyaga, J., et al. (2016). Ebola Virus Disease Is
- 1098 Characterized by Poor Activation and Reduced Levels of Circulating CD16+ Monocytes. J.
- 1099 Infect. Dis. 214, S275-S280.
- 1100 Massoni-Badosa, R., Iacono, G., Moutinho, C., Kulis, M., Palau, N., Marchese, D., Rodríguez-
- 1101 Ubreva, J., Ballestar, E., Rodriguez-Esteban, G., Marsal, S., et al. (2020). Sampling time-
- dependent artifacts in single-cell genomics studies. Genome Biol. 21, 112.
- 1103 McKechnie, J.L., and Blish, C.A. (2020). The innate immune system: fighting on the front lines or
- fanning the flames of COVID-19? Cell Host Microbe.
- 1105 Mei, H.E., Leipold, M.D., Schulz, A.R., Chester, C., and Maecker, H.T. (2015). Barcoding of Live
- Human Peripheral Blood Mononuclear Cells for Multiplexed Mass Cytometry. J. Immunol. *194*,
- 1107 2022–2031.
- 1108 Mei, H.E., Leipold, M.D., and Maecker, H.T. (2016). Platinum-conjugated antibodies for
- application in mass cytometry. Cytom. Part A 89, 292–300.
- 1110 Mengos, A.E., Gastineau, D.A., and Gustafson, M.P. (2019). The CD14+HLA-DrIO/NEG
- 1111 monocyte: An immunosuppressive phenotype that restrains responses to cancer
- immunotherapy. Front. Immunol. 10.
- Merad, M., and Martin, J.C. (2020). Pathological inflammation in patients with COVID-19: a key
- role for monocytes and macrophages. Nat. Rev. Immunol.
- 1115 Monneret, G., Lepape, A., Voirin, N., Bohé, J., Venet, F., Debard, A.L., Thizy, H., Bienvenu, J.,
- Gueyffier, F., and Vanhems, P. (2006). Persisting low monocyte human leukocyte antigen-DR
- expression predicts mortality in septic shock. Intensive Care Med. 32, 1175–1183.
- 1118 Naranjo-Gómez, J.S., Castillo, J.A., Rojas, M., Restrepo, B.N., Diaz, F.J., Velilla, P.A., and
- 1119 Castaño, D. (2019). Different phenotypes of non-classical monocytes associated with systemic
- inflammation, endothelial alteration and hepatic compromise in patients with dengue.
- 1121 Immunology *156*, 147–163.

1122 Ng, L.G., Ostuni, R., and Hidalgo, A. (2019). Heterogeneity of neutrophils. Nat. Rev. Immunol.

- 1123 *19*, 255–265.
- 1124 Ni, L., Ye, F., Cheng, M.L., Feng, Y., Deng, Y.Q., Zhao, H., Wei, P., Ge, J., Gou, M., Li, X., et al.
- 1125 (2020). Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19
- 1126 Convalescent Individuals. Immunity.
- Niu, J., Sun, Y., Chen, B., Zheng, B., Jarugumilli, G.K., Walker, S.R., Hata, A.N., Mino-Kenudson,
- M., Frank, D.A., and Wu, X. (2019). Fatty acids and cancer-amplified ZDHHC19 promote STAT3
- activation through S-palmitoylation. Nature.
- 1130 Pellin, D., Loperfido, M., Baricordi, C., Wolock, S.L., Montepeloso, A., Weinberg, O.K., Biffi, A.,
- 1131 Klein, A.M., and Biasco, L. (2019). A comprehensive single cell transcriptional landscape of
- human hematopoietic progenitors. Nat. Commun. 10.
- 1133 Perlman, S., and Dandekar, A.A. (2005). Immunopathogenesis of coronavirus infections:
- 1134 Implications for SARS. Nat. Rev. Immunol. 5, 917–927.
- 1135 Pfeiler, S., Massberg, S., and Engelmann, B. (2014). Biological basis and pathological relevance
- of microvascular thrombosis. Thromb. Res. 133.
- 1137 Pillay, J., Kamp, V.M., Van Hoffen, E., Visser, T., Tak, T., Lammers, J.W., Ulfman, L.H., Leenen,
- 1138 L.P., Pickkers, P., and Koenderman, L. (2012). A subset of neutrophils in human systemic
- inflammation inhibits T cell responses through Mac-1. J. Clin. Invest. 122, 327–336.
- Popescu, D.M., Botting, R.A., Stephenson, E., Green, K., Webb, S., Jardine, L., Calderbank, E.F.,
- Polanski, K., Goh, I., Efremova, M., et al. (2019). Decoding human fetal liver haematopoiesis.
- 1142 Nature *574*, 365–371.
- 1143 Qi, F., Qian, S., Zhang, S., and Zhang, Z. (2020). Single cell RNA sequencing of 13 human tissues

- identify cell types and receptors of human coronaviruses. Biochem. Biophys. Res. Commun.
- Remy, K.E., Brakenridge, S.C., Francois, B., Daix, T., Deutschman, C.S., Monneret, G., Jeannet,
- 1146 R., Laterre, P.-F., Hotchkiss, R.S., and Moldawer, L.L. (2020). Immunotherapies for COVID-19:
- lessons learned from sepsis. Lancet Respir. Med. 2, 2–5.
- Reyes, M., Filbin, M.R., Bhattacharyya, R.P., Billman, K., Eisenhaure, T., Hung, D.T., Levy, B.D.,
- Baron, R.M., Blainey, P.C., Goldberg, M.B., et al. (2020). An immune-cell signature of bacterial
- 1150 sepsis. Nat. Med. *26*, 333–340.
- 1151 Reymond, N., Imbert, A.M., Devilard, E., Fabre, S., Chabannon, C., Xerri, L., Farnarier, C.,
- 1152 Cantoni, C., Bottino, C., Moretta, A., et al. (2004). DNAM-1 and PVR regulate monocyte
- migration through endothelial junctions. J. Exp. Med. 199, 1331–1341.
- Riegel, A., Maurer, T., Prior, B., Stegmaier, S., Heppert, V., Wagner, C., and Hänsch, G.M. (2012).
- Human polymorphonuclear neutrophils express RANK and are activated by its ligand, RANKL.
- 1156 Eur. J. Immunol. 42, 975–981.
- 1157 Ritchie, A.I., and Singanayagam, A. (2020). Immunosuppression for hyperinflammation in
- 1158 COVID-19: a double-edged sword? Lancet 395, 1111.
- Robinson, M.D., Nowicka, M., Krieg, C., Weber, L.M., Hartmann, F.J., Guglietta, S., Becher, B.,
- and Levesque, M.P. (2017). CyTOF workflow: Differential discovery in high-throughput high-
- dimensional cytometry datasets. F1000Research 6.
- 1162 Salomé, B., and Mahmood, Z. (2020). Modulation of immune crosstalk in COVID-19. Nat. Rev.
- 1163 Immunol.
- 1164 Sander, L.E., Sackett, S.D., Dierssen, U., Beraza, N., Linke, R.P., Müller, M., Blander, J.M.,
- 1165 Tacke, F., and Trautwein, C. (2010). Hepatic acute-phase proteins control innate immune
- responses during infection by promoting myeloid-derived suppressor cell function. J. Exp. Med.
- 1167 *207*, 1453–1464.
- 1168 De Santo, C., Salio, M., Masri, S.H., Lee, L.Y.H., Dong, T., Speak, A.O., Porubsky, S., Booth, S.,
- 1169 Veerapen, N., Besra, G.S., et al. (2008). Invariant NKT cells reduce the immunosuppressive
- activity of influenza A virus-induced myeloid-derived suppressor cells in mice and humans. J.
- 1171 Clin. Invest. 118, 4036–4048.
- 1172 Scapini, P., Marini, O., Tecchio, C., and Cassatella, M.A. (2016). Human neutrophils in the saga
- of cellular heterogeneity: insights and open questions. Immunol. Rev. 273, 48–60.
- 1174 Schultze, J.L., Mass, E., and Schlitzer, A. (2019). Emerging Principles in Myelopoiesis at
- 1175 Homeostasis and during Infection and Inflammation. Immunity *50*, 288–301.
- 1176 Schulz, A.R., and Mei, H.E. (2019). Surface barcoding of live PBMC for multiplexed mass
- 1177 cytometry. In Methods in Molecular Biology, (Humana Press Inc.), pp. 93–108.
- 1178 Schulz, A.R., Baumgart, S., Schulze, J., Urbicht, M., Grützkau, A., and Mei, H.E. (2019).
- 1179 Stabilizing Antibody Cocktails for Mass Cytometry. Cytom. Part A *95*, 910–916.

1180 Silvestre-Roig, C., Fridlender, Z.G., Glogauer, M., and Scapini, P. (2019). Neutrophil Diversity in

Health and Disease. Trends Immunol. 40, 565–583.

1182 Stiel, L., Meziani, F., and Helms, J. (2018). Neutrophil Activation during Septic Shock. Shock 49,

- 1183 371–384.
- 1184 Sungnak, W., Huang, N., Bécavin, C., Berg, M., Queen, R., Litvinukova, M., Talavera-López, C.,
- Maatz, H., Reichart, D., Sampaziotis, F., et al. (2020). SARS-CoV-2 entry factors are highly
- expressed in nasal epithelial cells together with innate immune genes. Nat. Med.
- 1187 Tak, T., Wijten, P., Heeres, M., Pickkers, P., Scholten, A., Heck, A.J.R., Vrisekoop, N., Leenen,
- L.P., Borghans, J.A.M., Tesselaar, K., et al. (2017). Human CD62Ldim neutrophils identified as
- a separate subset by proteome profiling and in vivo pulse-chase labeling. Blood 129, 3476-
- 1190 3485.

- Testa, U., Riccioni, R., Diverio, D., Rossini, A., Lo Coco, F., and Peschle, C. (2004). Interleukin-3 receptor in acute leukemia. Leukemia *18*, 219–226.
- Thomas, M.P., Whangbo, J., McCrossan, G., Deutsch, A.J., Martinod, K., Walch, M., and Lieberman, J. (2014). Leukocyte Protease Binding to Nucleic Acids Promotes Nuclear
- Localization and Cleavage of Nucleic Acid Binding Proteins. J. Immunol. 192, 5390–5397.
- 1196 Uhel, F., Azzaoui, I., Grégoire, M., Pangault, C., Dulong, J., Tadié, J.M., Gacouin, A., Camus, C.,
- 1197 Cynober, L., Fest, T., et al. (2017). Early expansion of circulating granulocytic myeloid-derived suppressor cells predicts development of nosocomial infections in patients with sepsis. Am. J.
- 1199 Respir. Crit. Care Med. *196*, 315–327.
- Veglia, F., Perego, M., and Gabrilovich, D. (2018). Myeloid-derived suppressor cells coming of age review-article. Nat. Immunol. *19*, 108–119.
- Volkmann, J., Schmitz, J., Nordlohne, J., Dong, L., Helmke, A., Sen, P., Immenschuh, S., Bernhardt, W.M., Gwinner, W., Bräsen, J.H., et al. (2020). Kidney injury enhances renal G-CSF
- 1204 expression and modulates granulopoiesis and human neutrophil CD177 in vivo. Clin. Exp.
- 1205 Immunol. 199, 97–108.
- Wang, B., Li, R., Lu, Z., and Huang, Y. (2020a). Does comorbidity increase the risk of patients with covid-19: Evidence from meta-analysis. Aging (Albany. NY). *12*, 6049–6057.
- 1208 Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., Wang, B., Xiang, H., Cheng, Z., Xiong, Y.,
- et al. (2020b). Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus-
- 1210 Infected Pneumonia in Wuhan, China. JAMA J. Am. Med. Assoc. 323, 1061–1069.
- 1211 Wilk, A.J., Rustagi, A., Zhao, N.Q., Roque, J., Martinez-Colon, G.J., McKechnie, J.L., Ivison, G.T.,
- Ranganath, T., Vergara, R., Hollis, T., et al. (2020). A single-cell atlas of the peripheral immune
- response to severe COVID-19. MedRxiv 2020.04.17.20069930.
- Wölfel, R., Corman, V.M., Guggemos, W., Seilmaier, M., Zange, S., Müller, M.A., Niemeyer, D.,
- Jones, T.C., Vollmar, P., Rothe, C., et al. (2020). Virological assessment of hospitalized patients
- with COVID-2019. Nature.
- 1217 Wu, Z., and McGoogan, J.M. (2020). Characteristics of and Important Lessons from the
- 1218 Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314
- 1219 Cases from the Chinese Center for Disease Control and Prevention. JAMA J. Am. Med. Assoc.
- 1220 323, 1239–1242.
- 1221 Wu, F., Zhao, S., Yu, B., Chen, Y.M., Wang, W., Song, Z.G., Hu, Y., Tao, Z.W., Tian, J.H., Pei,
- 1222 Y.Y., et al. (2020). A new coronavirus associated with human respiratory disease in China.
- 1223 Nature *579*, 265–269.
- 1224 Xintian, X.I.A., Minyong, W.E.N., Shaofeng, Z., Jing, H.E., Weitao, C., Affiliated, F., and Medicine,
- 1225 C. (2020). [An Increased Neutrophil/Lymphocyte Ratio Is an Early Warning Signal of Severe
- 1226 COVID-19]. J South Med Univ 40, 333–336.
- 1227 Xu, Z., Shi, L., Wang, Y., Zhang, J., Huang, L., Zhang, C., Liu, S., Zhao, P., Liu, H., Zhu, L., et al.
- 1228 (2020). Pathological findings of COVID-19 associated with acute respiratory distress syndrome.
- 1229 Lancet Respir. Med. 8, 420–422.
- 1230 You, Q., He, D.M., Shu, G.F., Cao, B., Xia, Y.Q., Xing, Y., Ni, M., Chen, J.F., Shi, S.L., Gu, H.F.,
- et al. (2019). Increased formation of neutrophil extracellular traps is associated with gut leakage
- in patients with type 1 but not type 2 diabetes. J. Diabetes 11, 665–673.
- Younos, I.H., Abe, F., and Talmadge, J.E. (2015). Myeloid-derived suppressor cells: Their role in
- the pathophysiology of hematologic malignancies and potential as therapeutic targets. Leuk.
- 1235 Lymphoma.
- 1236 Yu, G., Wang, L.G., Han, Y., and He, Q.Y. (2012). ClusterProfiler: An R package for comparing
- biological themes among gene clusters. Omi. A J. Integr. Biol. 16, 284–287.

- Zhang, N., Zhao, H., and Zhang, L. (2018). Fatty Acid Synthase Promotes the Palmitoylation of Chikungunya Virus nsP1. J. Virol. 93.
- Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., Xiang, J., Wang, Y., Song, B., Gu, X., et al. (2020a). Clinical course and risk factors for mortality of adult inpatients with COVID-19 in
- Wuhan, China: a retrospective cohort study. Lancet 395, 1054–1062.
- 1243 Zhou, P., Yang, X. Lou, Wang, X.G., Hu, B., Zhang, L., Zhang, W., Si, H.R., Zhu, Y., Li, B., Huang,
- 1244 C.L., et al. (2020b). A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature *579*, 270–273.
- Zhou, Z., Ren, L., Zhang, L., Zhong, J., Xiao, Y., Jia, Z., Guo, L., Yang, J., Wang, C., Jiang, S.,
 et al. (2020c). Overly Exuberant Innate Immune Response to SARS-CoV-2 Infection. SSRN
- 1248 Electron. J.

- 1249 Ziegler, C.G.K., Allon, S.J., Nyquist, S.K., Mbano, I.M., Miao, V.N., Tzouanas, C.N., Cao, Y.,
- Yousif, A.S., Bals, J., Hauser, B.M., et al. (2020). SARS-CoV-2 Receptor ACE2 Is an Interferon-
- Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets
- 1252 across Tissues. Cell 0.
- 1253 Ziying Ong, E., Fu Zi Chan, Y., Leong, W.Y., Mei Ying Lee, N., Kalimuddin, S., and Mohamed
- Haja Mohideen, S. (2020). A dynamic immune response shapes COVID-19 progression. Cell 0.
- Zuo, Y., Yalavarthi, S., Shi, H., Gockman, K., Zuo, M., Madison, J.A., Blair, C.N., Weber, A.,
- Barnes, B.J., Egeblad, M., et al. (2020). Neutrophil extracellular traps in COVID-19. JCI Insight.

Acknowledgements

1258

1259

1260 1261

12621263

1264

1265

1266 1267

1268

1269

1270

1271

1272

1273 1274 1275

1276

1288

1289

1290

1291

1292

We thank Michael Kraut and Heidi Theis for technical assistance.

Deutsche COVID-19 Omics Initiative (DeCOI)

Robert Bals, Alexander Bartholomäus, Anke Becker, Ezio Bonifacio, Peer Bork, Thomas Clavel, Maria Colome-Tatche, Andreas Diefenbach, Alexander Dilthey, Nicole Fischer, Konrad Förstner, Julien Gagneur, Alexander Goesmann, Torsten Hain, Michael Hummel, Stefan Janssen, René Kallies, Birte Kehr, Andreas Keller, Sarah Kim-Hellmuth, Christoph Klein, Oliver Kohlbacher, Jan Korbel, Ingo Kurth, Markus Landthaler, Yang Li, Kerstin Ludwig, Oliwia Makarewicz, Manja Marz, Alice McHardy, Christian Mertes, Markus Nöthen, Peter Nürnberg, Uwe Ohler, Stephan Ossowski, Jörg Overmann, Klaus Pfeffer, Alfred Pühler, Nikolaus Rajewsky, Markus Ralser, Olaf Rieß, Stephan Ripke, Ulisses Nunes da Rocha, Philip Rosenstiel, Antoine-Emmanuel Saliba, Leif Erik Sander, Birgit Sawitzki, Philipp Schiffer, Joachim L. Schultze, Alexander Sczyrba, Oliver Stegle, Jens Stoye, Fabian Theis, Janne Vehreschild, Jörg Vogel, Max von Kleist, Andreas Walker, Jörn Walter, Dagmar Wieczorek, John Ziebuhr

Funding

1277 This work was supported by the German Research Foundation (DFG, SFB-TR84 #114933180 to 1278 L.E.S., S.H., A.H., N.S., C.D.; INST 37/1049-1, INST 216/981-1, INST 257/605-1, INST 269/768-1279 1 and INST 217/988-1, INST 217/577-1 to J.L.S; SFB TR57, SPP1937 to J.N.; GRK2157 to A.-E.S., ME 3644/5-1 to H.E.M.); the Berlin University Alliance (BUA, PreEP-Corona grant to L.E.S. 1280 , V.C. and C.D.), the Berlin Institute of Health (BIH, grant to L.E.S., A.H., C.D.); the HGF grant 1281 1282 sparse2big, the EU projects SYSCID (grant number 733100), and ERA CVD (grant number 00160389) to J.L.S.; the DZIF (TTU 04.816, 04.817 to J.N.); the Hector-Foundation (M89 to J.N.); 1283 the EU projects ONE STUDY (grant number 260687 to B.S.), BIO-DrIM (305147 to B.S.) and 1284 INsTRuCT (grant number 860003 to B.S.), the German Federal Ministry of Education and 1285 1286 Research (BMBF, project RAPID to C.D., S.H., A.H.), and a Charité ³R project to B.S. and S.H.; 1287 Radboud University Medical Centre Hypatia Grant (2018 to Y.L.).

Declaration of interests

The authors do not declare any conflict of interest

Author contributions

- 1293 Conceptualization: J. S-S., N.R., K.B., B.K., L.B., F.K., J.L.S, A.C.A., Y.L., J.N., B.S., A.-E.S., L.E.S.
- 1294 Methodology: J. S-S., D.P., T.K., S.B., L.B., E.D.D., M.G., D.W., M.B., T.S.K., A.S., O.D., H.M., A.R.S,


C.C., D.K., E.V., C.J.X., A.D., C.T., S.H., C.L.G., T.U., M.B., R.G., C.D., C.V.K., K.H. Software/data
analysis: J. S-S., N.R., K.B., S.S., B.Z., T.K., L.B., A.S., T.U., M.B. Investigation: J. S-S., K.B., T.P., A.H.,
M.H., J.L.S, A.C.A., M.W., Y.L., J.N., B.S., A.-E.S., L.E.S. Biospecimen/ enzyme resources: B.K., S.B.,
M.P., S.H., H.M.R., F.M., A.U., L.B.J., L.J., C.R.G., J.R., K.M.K, M.T., G.R., F.K., J.N., M.W. Writing –
Original Draft: J. S-S., N.R., K.B., L.B., E.D.D., C.M., J.L.S, A.C.A., Y.L., J.N., B.S., A.-E.S., L.E.S. Writing
Review & Editing: J. S-S., N.R., M.W., K.B., L.B., E.D.D., T.P., M.B., T.S.K., S.H., A.H., M.S., H.D.V.,
C.D., N.S., C.V.K., F.K., J.L.S, A.C.A., Y.L., J.N., B.S., A.-E.S., L.E.S.


Figures, figure titles and legends

Figure 1

1303

1304





1307

1308

1309

1310

1311

1312

1313

1314

1315

1316

1317

1318

1319

1320

1321

1322

1323


1324


1325


et al., 2016). *p<0.05, **p<0.01, ***p<0.001

Figure 1. Cohort definition and single-cell multi-omics analysis strategy. A, Processing pipeline for healthy and COVID-19 blood samples strategies used in this study. PBMC are isolated after Ficoll, labeled with cell hashing antibodies and loaded on a droplet-based single-cell RNA-seg (scRNA-seg) platform. Red blood cells (RBC) are lysed and immune cells are labeled with two panels of metal-labeled antibodies and processed with CyTOF platform. Number of subjects analyzed for each cohort included in this study is summarized on the right boxes. B, Features of the cohort classified according to WHO-defined clinical grades (3 to 8) and the time after first symptoms. C, Visualization of t-distributed stochastic neighbor embedding (viSNE)-automated analysis of CD45+ leukocytes, down-sampled to 70,000 cells, from our mass cytometry analyses using antibody panel 2 based on similarities in expression of 29 markers as defined in supplementary table 2. Cells are colored according to donor origin (blue = healthy controls, yellow = mild COVID-19. red = severe COVID-19) and major lineage subtypes. D, Box plots summarising differences in major immune cell lineage subtype composition of whole blood samples from COVID-19 patients with mild (n=5) or severe disease (n=6) course, agematched healthy controls utilized in mass cytometry (HC CyTOF, n=7) or measured by conventional or multi-colour flow cytometry (HC flow, n=18) as previously reported (Kverneland

Supplemental Figure 1








Supplemental Figure 1. Overview of sample analysis pipeline, major leukocyte lineages definition and quantification by CyTOF and MCFC.

A, Overview summarising sample analysis pipeline for single cell transcriptomics and proteomics of COVID-19 samples.

B, High resolution SPADE analysis with 400 target nodes and individual nodes aggregated to the indicated major immune cell lineages according to the expression of lineage specific cell marker such as CD14 for monocytes and CD15 for neutrophils of whole blood samples collected from COVID-19 patients and healthy controls and stained with CyTOF panel 1 and 2, respectively.

C, Box plots summarising differences in major immune cell lineage subtype composition of whole blood samples from the second cohort of COVID-19 patients showing either mild (n=2) or severe/critical disease (n=3) course, age-matched healthy controls (n=7) measured by conventional fluorochrome-based cytometry. **p<0.01.



1341 Figure 2. scRNA-seg of PBMC from patients of two independent cohorts reveals dynamic 1342 changes in the composition and the transcriptional states of myeloid cells in the 1343 peripheral blood in COVID-19 1344 Abbreviations: HC: Healthy control. 1345 A, UMAP visualization of 10x chromium scRNA-seg profiles of 48.085 PBMC purified by density 1346 gradient centrifugation of peripheral blood from 21 samples of different time points of 4 mild 1347 and 8 severe patients in cohort 1 colored according to the indicated cell type classification based 1348 on Louvain clustering, reference-based cell-type annotation and marker gene expression 1349 patterns. 1350 B, UMAP shown in (a) colored according to disease severity (yellow = mild COVID-19, red = 1351 severe COVID-19). 1352 C, Dot plot representation of the top 10 marker genes sorted by average log fold change 1353 determined for the indicated myeloid cell subsets in the PBMC data set of cohort 1 plotted across 1354 the subsets of both cohorts. 1355 **D**, UMAP visualization of BD rhapsody scRNA-seq profiles of 93.297 PBMC purified by density 1356 gradient centrifugation from peripheral blood from 35 samples of 6 mild and 5 severe and 2 control 1357 patients of different time points in cohort 2 colored according to the indicated cell type 1358 classification based on Louvain clustering, reference-based cell-type annotation and marker gene 1359 expression patterns (Suppl. Fig. 2A). 1360 E, Box plots visualizing the percentages of the indicated cell subsets of the total number of PBMCs

assessed per patient in the respective data set. Boxes are colored according to disease group

and dots according to the respective cohort of the sample. For neutrophils and immature


neutrophils only fresh PBMC samples were included.

1361

1362

1363


Supplemental Figure 2




Supplemental Figure 2. Cluster-specific marker gene expression shows inflammatory activation signatures of monocyte subsets and the appearance of neutrophil subsets in the PBMC fraction

- **A**, Dot plot representation of the top 10 marker genes sorted by average log fold change determined for the clusters depicted in the UMAP in Figure 2A.
 - **B**, Dot plot representation of the top 10 marker genes sorted by average log fold change determined for the clusters depicted in the UMAP in Figure 2C.

Figure 3



1376 Figure 3. Subjects with different COVID-19 stages display unique phenotypical and 1377 transcriptional monocyte signatures. 1378 A, Heatmap revealing differences in marker expression determined by mass cytometry (CyTOF) 1379 using antibody panel 1 of monocyte and dendritic cell cluster. Cell clusters are displayed in 1380 columns and marker identity is indicated in rows. MSI = marker staining intensity respective 1381 expression level, significance level for the comparisons i) healthy controls (HC, n=7) versus 1382 COVID-19 (upper row) as well as ii) mild (n=5) versus severe (n=6, lower row) are indicated using 1383 a grey scale on top of the heatmap. 1384 B, t-SNE plots of monocytes and dendritic cells, down-sampled to 70,000 cells, based on their 1385 similarities in expression of 35 markers as defined in supplementary table 2. Cells are colored 1386 according to parental subclusters (classical monocytes, non-classical monocytes, intermediate 1387 monocytes, myeloid dendritic cells, plasmacytoid dendritic cells), donor origin (blue = healthy controls, yellow = mild COVID-19, red = severe COVID-19) and expression intensity of CD226. 1388 1389 HLA-DR and CD11c. 1390 C, Dot plot representation of marker genes calculated for the clusters within the monocyte 1391 space of cohort 1. 1392 **D.** Gene ontology enrichment analysis of complete marker genes obtained for each identified 1393 monocyte population of cohort 1. E, UMAP visualization of 29,334 cells within the monocyte space of cohort 2. Cells are colored 1394 1395 according to the identified clusters. 1396 F, Cluster occupancy per patient over time. Coloring according to the clusters identified in 1397 Figure 3E. Vertical dashed lines indicate the time points at which the samples were taken. The 1398 violet bar below the individual patient data indicates the respective WHO classification. Patient 1399 IDs are shown on the right.



Supplemental Figure 3. Phenotypical and transcriptional differences of monocytes from

- 1403 mild and severe COVID-19
- 1404 A, Box plots summarizing differences in CD226, HLA-DRhigh, CD11c and CXCR3 expression
- within classical monocytes measured by mass cytometry in whole blood samples from cohort 1
- 1406 distinguishing between healthy controls (n=7), COVID-19 patients with mild (n=5) or
- 1407 severe/critical disease (n=6) course. *p<0.05, **p>0.01
- 1408 **B,** Violin plots representing expression of selected genes in monocyte clusters of cohort 1.
- 1409 Coloring according to cluster color in Figure 2
- 1410 **C**, Violin plots representing expression of selected genes in monocyte clusters of cohort 2.
- 1411 **D,** Back mapping of identified monocyte clusters of cohort 2 onto the PBMC UMAP in Figure 2.
- **E,** Dot plot representation of marker genes found in monocyte clusters of cohort 2.
- 1413 **F.** Visualization of the expression of selected genes in the UMAP of the monocyte space in cohort
- 1414 2.
- 1415 **G**, AUCell-based enrichment of gene signature derived from sepsis-associated monocytes
- 1416 (Reves et al., 2020) in monocytes of cohort 2 and plotting of the 'Area Under the Curve' (AUC)
- 1417 scores as violin plots. The horizontal lines in the violin plots represent the median of the respective
- 1418 AUC scores per cluster.
- 1419 **H.** Time-dependent change of IFI6 and ISG15 expression in monocytes of cohort 1. Significant
- changes determined by the Wilcoxon rank sum test are indicated (*** = pvalue < 0.001; n.s. = not
- 1421 significant).

Figure 4

1423

1424

1425




Figure 4. Immature and dysfunctional low-density neutrophils emerge in PBMC fractions.

- **A,** UMAP representation and clustering of the neutrophils identified in PBMC from cohort 1 (clusters 9 and 13 in Figure 2A).
- 1427 **B,** Dot plot visualization of the expression of the cluster-specific marker genes associated to each of clusters identified in panel A.
- 1429 C, Signature enrichment score of neutrophil progenitors derived from previous single-cell data.
 1430 AUC: Area under the curve.
- **D,** Violin plots giving the expression of selected activation genes across the neutrophil clusters identified in panel A.
- 1433 **E**, Expression of *ARG1* and *PD-L1* projected on the UMAP from panel A.

Supplemental Figure 4

1436


1437

1438

1439

1440

1441



Supplemental Figure 4. Additional analysis of dysfunctional neutrophils in PBMC fraction.

- **A,** Dot plot representation of marker genes associated to pre-neutrophils (pre-neutr), immature and mature neutrophils.
- **B**, Pie charts giving the proportion of cells in each cell cycle stage. The numbers refer to clusters as identified in the UMAP in Figure 4A.

Figure 5





Figure 5. Disbalance between increase in activated and potentially immunosuppressive neutrophils discriminates between mild and severe COVID-19 patients.

A, Heatmap revealing differences in marker expression determined by mass cytometry (CyTOF) using antibody panel 2 of identified neutrophil cell subcluster (1 to 7). Neutrophil cell clusters belonging to the identified subcluster are displayed in columns and marker identity is indicated in rows. MSI = marker staining intensity respective expression level, significance level for the comparisons i) healthy controls (HC) versus COVID-19 (upper row) as well as ii) mild versus severe (lower row) are indicated using a grey scale on top of the heatmap.

B, t-SNE plots of neutrophils, down-sampled to 70.000 cells, based on their similarities in expression of 29 markers as defined in supplementary table 2. Cells are colored according to


- neutrophil subcluster, donor origin (blue = healthy controls, yellow = mild COVID-19, red = severe
- 1456 COVID-19) and expression intensity of CD34, CD64, Siglec 8, RANK, RANKL, CD45, CD62L,
- 1457 CD123 and PD-L1.
- 1458 **C,** Bar graphs summarizing CD34, CD62L, CD123 and PD-L1 expression as % positive cells
- 1459 within neutrophils of whole blood samples from COVID-19 patients with mild (n=5) or severe
- 1460 disease (n=5) course and age-matched healthy controls (n=7). *p<0.05, **p<0.01
- 1461 **D-F**, Box plots summarizing time-dependent differences in total granulocytes and monocytes,
- non-classical monocytes (**D**) CD34, CD62L, CD123 and PD-L1 expressing neutrophils (**E**) as well
- as CD11c and CXCR3 expressing classical monocytes (F) measured by mass cytometry in whole
- blood samples from cohort 1 distinguishing between COVID-19 patients with mild (days 0-10:
- 1465 n=3, days 11-25: n=10) or severe/critical disease (days 0-10: n=5, days 11-25: n=5) course.
- 1466 *p<0.05, ****p<0.0001

Figure 6



- 1469 Figure 6. Delineation of suppressive mature neutrophils in late stage severe COVID-19.
- 1470 A, UMAP visualization of fresh blood samples from cohort 2 (PBMC and whole blood combined,
- 1471 88,177 cells, controls (ctrl = 12), COVID-19 mild (mild = 6), COVID-19 severe (severe = 8).
- 1472 **B,** UMAP visualization of the immature and mature neutrophils (30,019 cells) from Figure 6A after
- 1473 exclusion of one experimental batch (see Methods, controls (ctrl = 10), COVID-19 early mild = 1,
- 1474 COVID-19 severe (early = 2, late = 2)).
- 1475 **C,** Dot plot of selected top 6 marker genes ordered by average log fold-change highlighting the
- 1476 heterogeneity of the neutrophil space in b.
- 1477 **D**, Overview of functional nomenclature and marker genes for each cluster in the neutrophil space
- 1478 in COVID-19 and control patients.
- 1479 E, UMAP visualization of neutrophils showing the scaled expression of PD-L1 (CD274) with a
- clear enrichment in the Covid-19 specific clusters 2 and 0.
- 1481 **F,** Confusion matrix for each cluster in Figure 6B divided by disease severity and time point
- showing the enrichment of each patient group for each cluster; the scale is normalized for each
- 1483 cluster.

- 1484 **G**, Density plot of cell frequency by disease severity and time point overlaid on UMAP visualization
- 1485 of the neutrophil space.
- 1486 **H.** Dot plot of genes from different functional classes showing the differences of the neutrophil
- 1487 states (based on literature research).
- 1488 I, Transcription factor binding prediction results for clusters 0, 2 and 5 shown as networks of
- 1489 transcription factors and their targets among the specifically expressed genes for the given
- 1490 cluster. Edges represent predicted transcriptional regulation. Transcription factors in the inner
- 1491 circle and their predicted target genes in the outer circle are represented as nodes sized and
- 1492 colored according to the scaled expression level across all clusters. Top 10 highest connected
- transcription factors and those exclusively predicted for the cluster as well as the top 5 highest
- 1494 connected target genes together with a literature-based selection of targets are labeled.



- 1497 Supplemental Figure 6. Overview of scRNA-seq dataset from cohort 2 and additional
- 1498 characterization of suppressive neutrophils.
- 1499 **A,** UMAP (right) of the complete scRNA-seq dataset from cohort 2 (frozen PBMC, fresh PBMC,
- 1500 fresh whole blood) and violin plot of number of genes and transcripts expressed in the PBMC VS.
- 1501 granulocyte fraction across the different data sets of cohort 2 (right). Violin plots are split into
- 1502 granulocytes (left) and PBMC (right). The table below indicates the number of cells per
- 1503 experimental condition with the number of samples in brackets.
- 1504 **B,** Box plot of cell type frequencies identified by scRNA-seq in fresh whole blood samples after
- erythrocyte lysis comparing 23 samples from 11 control individuals, 4 samples from mild and 8
- samples from severe COVID-19 patients at early and late timepoints.
- 1507 **C,** Comparison between cell frequencies identified by scRNA-seq and MCFC, pearson's
- 1508 correlation between the mean of each cell population (left) and stacked bar chart sorted by
- 1509 disease severity.
- 1510 **D,** Enrichment of signature genes from the neutrophil clusters from cohort 2 on the UMAP
- 1511 visualization of cohort 1.
- 1512 **E**, Dot plot representation of marker genes taken from literature classifying different neutrophil
- 1513 subsets.
- 1514 **F.** UMAP representation of neutrophils showing the scaled expression of CD62L (SELL) and
- 1515 CD64 (FCGR1A) with a clear enrichment in the COVID-19 specific clusters 2 and 0.
- 1516 **G**, Dot plot visualization of selected significantly enriched Gene Ontology terms and KEGG
- pathways for each cluster from the neutrophil space.
- 1518 **H.** Diffusion map dimensionality reduction of the main neutrophil clusters 9, 8, 2, 0 and 6 from the
- 1519 severe COVID-19 patients (top) and diffusion pseudotime visualized on the diffusion map
- indicating the transition probability of the different clusters in the following order: 9 8 2 0 6
- 1521 (bottom).
- 1522 I, Genes specific for each cluster visualized along the diffusion pseudotime (top) with the density
- of each cluster along the pseudotime (bottom) highlighting the proposed order of differentiation of
- the different neutrophil subsets.
- 1525 H, Transcription factor binding prediction results for clusters 8 and 9 shown as networks of
- 1526 transcription factors and their targets among the specifically expressed genes for the given
- 1527 cluster. Edges represent predicted transcriptional regulation. Transcription factors in the inner
- 1528 circle and their predicted target genes in the outer circle are represented as nodes sized and
- 1529 colored according to the scaled expression level across all clusters. Top 10 highest connected
- 1530 transcription factors and those exclusively predicted for the cluster as well as the top 5 highest
- 1531 connected target genes together with a literature-based selection of targets are labeled.

Supplemental Table 1. Cohort outline used to perform scRNA-seq, mass cytometry and MCFC (multi-colour flow cytometry).

Supplemental Table 2. Detailed information on antibody panels used for mass cytometry analysis.

Supplemental Table 3. List of antibodies used for MCFC.